(FILE 'HOME' ENTERED AT 10:30:19 ON 06 JUN 2000)

FILE 'STNGUIDE' ENTERED AT 10:30:35 ON 06 JUN 2000

FILE 'REGISTRY' ENTERED AT 10:32:56 ON 06 JUN 2000
L1 1 S OLANZAPINE/CN

FILE 'CAPLUS' ENTERED AT 10:34:06 ON 06 JUN 2000
L2 299 S L1

FILE 'REGISTRY' ENTERED AT 10:35:14 ON 06 JUN 2000
L3 0 S PAMOATE DIMETHANOLATE/CN
L4 0 S PAMOATE/CN
L5 0 S PAMOATE MONOHYDRATE/CN

FILE 'CAPLUS' ENTERED AT 10:37:39 ON 06 JUN 2000
S PAMOATE DIMETHANOLATE/CN

FILE 'REGISTRY' ENTERED AT 10:39:03 ON 06 JUN 2000
L6 0 S PAMOATE DIMETHANOLATE/CN

FILE 'CAPLUS' ENTERED AT 10:39:11 ON 06 JUN 2000

FILE 'CAPLUS' ENTERED AT 10:39:30 ON 06 JUN 2000
L7 351 S PAMOATE
L8 2 S L2 AND L7
SELECT RN L8 1

FILE 'REGISTRY' ENTERED AT 10:41:29 ON 06 JUN 2000
L9 16 S E1-16

FILE 'CAPLUS' ENTERED AT 10:42:00 ON 06 JUN 2000
L10 2 S L9 AND L8

FILE 'REGISTRY' ENTERED AT 10:49:15 ON 06 JUN 2000
L11 1 S 221373-09-7/RN
L12 1 S 221373-12-2/RN
L13 1 S 221373-14-4/RN
L14 1 S 221373-18-8/RN
L15 1 S 263017-43-2/RN
L16 1 S 263017-44-3/RN

FILE 'CAPLUS' ENTERED AT 10:52:47 ON 06 JUN 2000
L17 2 S L11-L16
L18 2 S L10 AND L17
L19 91 S PHARMACEUTICAL SALT
L20 0 S L2 AND L19
L21 73 S L2 AND PATENT/DT
L22 226 S L2 NOT L21
L23 133 S PD>1997 AND L22
L24 93 S L22 NOT L23

FILE 'REGISTRY' ENTERED AT 10:59:15 ON 06 JUN 2000
L25 1 S 130-85-8/RN

FILE 'CAPLUS' ENTERED AT 10:59:48 ON 06 JUN 2000

L26 95 S L25
S L26 RN

FILE 'REGISTRY' ENTERED AT 11:00:44 ON 06 JUN 2000

FILE 'CAPLUS' ENTERED AT 11:00:45 ON 06 JUN 2000
S 130-85-8/CRN

FILE 'REGISTRY' ENTERED AT 11:00:58 ON 06 JUN 2000
L27 598 S 130-85-8/CRN

FILE 'CAPLUS' ENTERED AT 11:01:01 ON 06 JUN 2000
L28 524 S L27

=> s l2 and l28

L29 2 L2 AND L28

=> d bib abs hitstr l31 1-5

L31 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2000 ACS
AN 2000:227510 CAPLUS
DN 132:256034
TI 2-Methylthienobenzodiazepine formulation
IN Bunnell, Charles Arthur; Ferguson, Thomas Harry; Hendriksen, Barry Arnold;
Sanchez-Felix, Manuel Vicente; Tupper, David Edward
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000018408	A1	20000406	WO 1999-US6417	19990324

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1998-163768 19980930
US 1998-163769 19980930
AB The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates. Thus, olanzapine was prepd. and mixed with cholesterol in methylene chloride. An aq. soln. of PVA was added to the above soln. and the mixt. was passed through 100- and 230-mesh sieves, and the particles thus obtained were allowed to dry.
IT **205485-16-1P 221373-09-7P 221373-12-2P 221373-14-4P 221373-18-8P 263017-43-2P 263017-44-3P**
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(methylthienobenzodiazepine formulations)
RN 205485-16-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-, dihydrate (9CI) (CA INDEX NAME)



●2 H_2O

RN 221373-09-7 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 130-85-8
CMF C23 H16 O6



RN 221373-12-2 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with methanol and 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (1:2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 130-85-8
CMF C23 H16 O6



CM 3

CRN 67-56-1
CMF C H4 O

H_3C-OH

RN 221373-14-4 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine and tetrahydrofuran (1:1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 130-85-8
CMF C23 H16 O6



CM 3

CRN 109-99-9
CMF C4 H8 O

RN 221373-18-8 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (1:1), monohydrate (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 130-85-8
CMF C23 H16 O6



RN 263017-43-2 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine

and 2-propanone (1:2:2) (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 130-85-8
CMF C23 H16 O6



CM 3

CRN 67-64-1
CMF C3 H6 O



RN 263017-44-3 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (1:2), dihydrate (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 130-85-8
CMF C23 H16 O6



RE.CNT 1
(1) Cygnus Inc; WO 9709985 A1 1997 CAPLUS

L21 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2000 ACS
AN 1999:752863 CAPLUS
DN 131:346550
TI Atypical antipsychotic agent-serotonin reuptake inhibitor combinations for
therapy of refractory depression
IN Tollefson, Gary Dennis
PA Eli Lilly and Co., USA
SO Eur. Pat. Appl., 15 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI	EP 958824	A2	19991124	EP 1999-303969	19990521
	EP 958824	A3	19991201		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	WO 9961027	A1	19991202	WO 1999-US11276	19990521
	W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI US 1998-86444 19980522

AB Methods and compns. are provided for the treatment of depressive states refractory to treatment with traditional antidepressive therapies alone. These methods and compns. employ a compd. having activity as an atypical antipsychotic (e.g. olanzapine) and a serotonin reuptake inhibitor (e.g. fluoxetine). This invention also provides methods of providing rapid onset treatments of major depression which employing a compd. having activity as an atypical antipsychotic and a serotonin reuptake inhibitor.

IT **250603-12-4 250603-17-9 250603-18-0**
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(atypical antipsychotic agent-serotonin reuptake inhibitor combinations
for therapy of refractory depression)

RN 250603-12-4 CAPLUS

CN Benzenepropanamine, N-methyl-.gamma.-[4-(trifluoromethyl)phenoxy]-, hydrochloride, mixt. with 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 56296-78-7

CMF C17 H18 F3 N O . Cl H



● HCl

RN 250603-17-9 CAPLUS
CN 1-Naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-, (1S,4S)-, mixt. with 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 79617-96-2
CMF C17 H17 Cl2 N

Absolute stereochemistry. Rotation (+).



RN 250603-18-0 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
, mixt. with (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 61869-08-7
CMF C19 H20 F N O3

Absolute stereochemistry. Rotation (-).



L31 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2000 ACS
AN 1999:233762 CAPLUS
DN 130:257362
TI Methylthienobenzodiazepine derivative antipsychotic drug formulation.
IN Allen, Douglas James; Dekemper, Kurt Douglas; Ferguson, Thomas Harry; Garvin, Stuart James; Murray, Linda Cameron; Brooks, Norman Dale; Bunnell, Charles Arthur; Hendriksen, Barry Arnold; Mascarenhas, Snehlata Singh; Shinkle, Sharon Louise; Sanchez-Felix, Manuel Vicente; Tupper, David Edward
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9916313	A1	19990408	WO 1998-US20426	19980930
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9895914	A1	19990423	AU 1998-95914	19980930

PRAI US 1997-60493 19970930
WO 1998-US20426 19980930

AB The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2.3-b][1.5]benzodiazepine (olanzapine) (prepn. given) or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.

IT **221373-09-7P 221373-12-2P 221373-14-4P 221373-18-8P 221373-22-4P 221373-25-7P 221373-29-1P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and formulation of)

RN 221373-09-7 CAPLUS

Applicants

CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 130-85-8
CMF C23 H16 O6



RN 221373-12-2 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with methanol and 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (1:2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 130-85-8
CMF C23 H16 O6



CM 3

CRN 67-56-1
CMF C H4 O

H_3C-OH

RN 221373-14-4 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine and tetrahydrofuran (1:1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 130-85-8
CMF C23 H16 O6



CM 3

CRN 109-99-9
CMF C4 H8 O

RN 221373-18-8 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (1:1), monohydrate (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 130-85-8
CMF C23 H16 O6



RN 221373-22-4 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine and 2-propanone (1:2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 130-85-8
CMF C23 H16 O6



CM 3

CRN 67-64-1
CMF C3 H6 O



RN 221373-25-7 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (1:2), monohydrate (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 130-85-8
CMF C23 H16 O6



RN 221373-29-1 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (1:1), dihydrate (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 130-85-8
CMF C23 H16 O6



RE.CNT 2
(1) Beasley Jr; US 5602897 A 1997
(2) Chakrabarti; US 5229382 A 1993

L31 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2000 ACS
AN 1998:204464 CAPLUS
DN 128:275100
TI Intermediates and process for preparing olanzapine
IN Bunnell, Charles Arthur; Larsen, Samuel Dean; Nichols, John Richard; Reutzel, Susan Marie; Stephenson, Gregory Alan
PA Eli Lilly and Co., USA
SO Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 831098	A2	19980325	EP 1997-307383	19970922
EP 831098	A3	19980429		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 9812199	A1	19980326	WO 1997-US16499	19970918

W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9744841	A1	19980414	AU 1997-44841	19970918
BR 9712100	A	19990831	BR 1997-12100	19970918
CN 1234802	A	19991110	CN 1997-198137	19970918
US 6020487	A	20000201	US 1997-935884	19970923
NO 9901382	A	19990322	NO 1999-1382	19990322

PRAI US 1996-26487 19960923
WO 1997-US16499 19970918

AB The present invention provides a process for prepg. olanzapine and dihydrate polymorphs. Olanzapine was prepd. from a known intermediate and later converted to its dihydrate. The x-ray powder anal. of the compd. was carried out.

IT **205485-16-1P**
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(intermediates and process for prepg. olanzapine)

RN 205485-16-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-, dihydrate (9CI) (CA INDEX NAME)



●2 H_2O

L31 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2000 ACS
AN 1996:656468 CAPLUS
DN 125:301028
TI Preparation of olanzapine solvates
IN Bunnell, Charles Arthur; Hendriksen, Barry Arnold; Hotten, Terrence Michael; Larsen, Samuel Dean; Tupper, David Edward
PA Lilly, Eli, and Co., USA; Lilly Industries Ltd.
SO Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW
DT Patent

LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 733634	A1	19960925	EP 1996-301999	19960322
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5631250	A	19970520	US 1995-410474	19950324
	US 5703232	A	19971230	US 1996-586431	19960116
	WO 9630374	A1	19961003	WO 1996-US3854	19960322
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9652578	A1	19961016	AU 1996-52578	19960322
	AU 9654279	A1	19961016	AU 1996-54279	19960322
	AU 706471	B2	19990617		
	GB 2313835	A1	19971210	GB 1997-19819	19960322
	GB 2313835	B2	19980916		
	DE 19681286	T	19980402	DE 1996-19681286	19960322
	BR 9607790	A	19980707	BR 1996-7790	19960322
	JP 11502535	T2	19990302	JP 1996-529532	19960322
	AT 9609021	A	20000115	AT 1996-9021	19960322
	SE 9703205	A	19970905	SE 1997-3205	19970905
	FI 9703750	A	19970922	FI 1997-3750	19970922
	NO 9704365	A	19970922	NO 1997-4365	19970922
	DK 9701089	A	19971112	DK 1997-1089	19970923
PRAI	US 1995-409566	19950324			
	US 1995-410474	19950324			
	WO 1996-US3854	19960322			
	WO 1996-US3917	19960322			

AB The invention provides MeOH, EtOH, and PrOH solvates of olanzapine with improved properties characterized by x-ray spectra.

IT **182808-49-7P 182808-50-0P 182808-51-1P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of olanzapine solvates)

RN 182808-49-7 CAPLUS

CN Methanol, compd. with 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 67-56-1
CMF C H4 O

H_3C-OH

RN 182808-50-0 CAPLUS
CN Ethanol, compd. with 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 64-17-5
CMF C2 H6 O

H_3C-CH_2-OH

RN 182808-51-1 CAPLUS
CN 1-Propanol, compd. with 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 71-23-8
CMF C3 H8 O

$H_3C-CH_2-CH_2-OH$

=> d bib abs hitstr l21 1-73

L21 ANSWER 1 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 2000:284006 CAPLUS
DN 132:274341
TI Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
IN Fogel, Barry S.
PA Synchroneuron, LLC, USA
SO U.S., 16 pp., Cont.-in-part of U.S. 5,866,585.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI US 6057373 A 20000502 US 1999-224829 19990104
US 5866585 A 19990202 US 1997-861801 19970522
WO 9936064 A2 19990722 WO 1999-US144 19990113
WO 9936064 A3 19991202
W: AU, CA, CH, CN, JP, MX, NZ
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
AU 9921041 A1 19990802 AU 1999-21041 19990113
PRAI US 1997-861801 19970522
US 1998-6641 19980113
US 1998-193892 19981118
US 1999-224829 19990104
WO 1999-US144 19990113

AB The invention describes a treatment for movement disorders, including tardive dyskinesia and tardive dystonia, and focal dystonias not due to neuroleptics, including blepharospasm, Meige syndrome, and occupational dystonias. The treatment of the invention uses agents that act as NMDA-type glutamate receptor antagonists. The invention also involves the use of an ion channel-blocking agent to augment the therapeutic action of the drug treatments described. A particularly preferred ion channel-blocking agent is magnesium.

IT **132539-06-1**, Olanzapine
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(NMDA receptor antagonist for treatment of tardive dyskinesia or other movement disorder)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



RE.CNT 107
(1) Alexander; Brit F Psychiat 1978, V133, P143 CAPLUS
(3) Andreassen; Pharmacology Biochemistry and Behavior 1994, V49, P309 CAPLUS
(6) Athanassenas; Journal of Clinical Psychopharmacology 1983, V3, P212 CAPLUS
(11) Britton; Life Sciences 1997, V60, P1729 CAPLUS
(22) Delfs; Exp Neurol 1995, V133, P175 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 2 OF 73 CAPLUS COPYRIGHT 2000 ACS

AN 2000:277835 CAPLUS
DN 132:298845
TI Therapy for improving cognition
IN De Nijs, Paul Leonce Irma; Parys, Wim Louis Julien
PA Janssen Pharmaceutica N.V., Belg.
SO PCT Int. Appl., 7 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000023057	A2	20000427	WO 1999-EP7804	19991012

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI EP 1998-203454 19981016
AB The present invention is concerned with pharmaceutical compns. comprising a carrier and as first active ingredient an atypical antipsychotic agent (I) and as second active ingredient an acetylcholinesterase inhibitor (II), each in an amt. producing a therapeutically beneficial effect in patients suffering from psychosis, or Alzheimer's disease or related dementias. The therapeutically beneficial effect can be a synergistic effect on the cognitive functioning of patients suffering from Alzheimer's disease or related dementias or the prevention of the further deterioration of cognition in the patients, or the redn. of adverse effects assocd. with one of the active ingredients by the other of the active ingredients. Preferred compns. comprise risperidone as the atypical antipsychotic and galantamine as the acetylcholinesterase inhibitor.
IT **132539-06-1**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutics for improving cognition contg. antipsychotic agent and acetylcholinesterase inhibitor)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 3 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 2000:260507 CAPLUS
DN 132:277760
TI Molecular markers for determining a patient's risk of developing agranulocytosis and the development of drugs not inducing the disease
IN Lee, John; Kauffman, Michael
PA Millennium Predictive Medicine, Inc., USA
SO PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000022109	A1	20000420	WO 1999-US23638	19991013

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1998-PV104100 19981013
AB The invention features methods for detg. whether a patient is likely to develop agranulocytosis, for example, as a result of treatment with pharmaceutical agents that adversely affect leukocytes or their progenitors in the bone marrow. Further, it encompasses methods for screening compds. to find those useful in treating or preventing agranulocytosis, as well as methods for treating a patient who is at risk of developing, or who has developed, agranulocytosis. The invention is based, in part, on the identification of differentially expressed genes, i.e., genes that are either overexpressed or underexpressed in bone marrow cells treated with clozapine, the expression being relative to that in untreated bone marrow cells or in bone marrow cells that have been treated with a compd. that does not alter expression of the differentially expressed genes of the invention (i.e., olanzapine).
IT **132539-06-1**, Olanzapine
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(mol. markers for detg. patient's risk of developing agranulocytosis and development of drugs not inducing disease)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RE.CNT 5
(1) Corzo; Blood 1995, V86(10), P3835 CAPLUS
(2) Dong; Mutations in the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia 1997, V11(1), P120 CAPLUS
(3) Rane; Biochimica et Biophysica Acta 1996, V1291, P60 CAPLUS
(4) Ritter; Biological Psychiatry 1997, V42(3), P155 CAPLUS
(5) Turbay; Blook 1997, V89(11), P4167 CAPLUS

L21 ANSWER 4 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 2000:260000 CAPLUS
DN 132:288772
TI Use of metformin to counteract weight gain associated with valproate and other psychotropic medications
IN Cottingham, Elizabeth Marie
PA Children's Hospital Research Foundation, USA; Morrison, John Ainslie
SO PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000021522	A1	20000420	WO 1999-US24262	19991015

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1998-PV104394 19981015
US 1999-416330 19991012
AB A method for minimizing the wt. gain side effect assocd. with psychotropic

treatment is disclosed. In the method, Metformin, a biguanide compd., is concurrently administered to a patient taking the psychotropic active. A pharmaceutical compn. contg. the combination of psychotropic active and Metformin is also disclosed. Psychotropic actives are selected from valproate, Risperdal, Lithobid, Zyprexa and Seroquel.

IT **132539-06-1**, Zyprexa
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(metformin to counteract wt. gain assocd. with valproate and other psychotropic medications)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



RE.CNT 8
(1) Abdallah, O; S T P PHARMA 1988, V4(1), P15 CAPLUS
(3) Karttunen, P; INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY, THERAPY, AND TOXICOLOGY 1983, V21(1), P31 CAPLUS
(6) Paolisso, G; EUROPEAN JOURNAL OF CLINICAL INVESTIGATION 1998, V28(6), P441 CAPLUS
(7) Pedersen, J; ACTA ENDOCRINOLOGICA 1968, V57(4), P683 CAPLUS
(8) Pentikainen, P; INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY, THERAPY, AND TOXICOLOGY 1986, V24(4), P213 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 5 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 2000:241564 CAPLUS
DN 132:288780
TI Methods of identifying inverse agonists of the serotonin 2a receptor, therapeutic and diagnostic methods, and test kit
IN Weiner, David; Brann, Mark R.
PA Acadia Pharmaceuticals Inc., USA
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000020636	A1	20000413	WO 1999-US21439	19991007

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1998-PV103317 19981007
US 1999-413626 19991006

AB A method for identifying compds. which act as inverse agonists of the 5-HT2A receptor comprises contacting a constitutively active 5-HT2A receptor with at least one test compd. and detg. any decrease in the level of basal activity of the receptor. The inverse agonists may be used in the treatment of schizophrenia and related psychoses.

IT **132539-06-1**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(serotonin 2a receptor inverse agonist identification, therapeutic and diagnostic methods, and test kit)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



RE.CNT 7
(1) Eggerickx, D; BIOCHEMICAL JOURNAL 1995, V309, P837 CAPLUS
(2) Grotewiel, M; FASEB JOURNAL, abstract 353 1994, V8(7), PA1319
(3) Herrick, D; WO 9838217 A 1998
(4) Inst Of Psychiatry; WO 9617081 A 1996
(6) Shenker, A; NATURE 1993, V365, P652 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 6 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 2000:227510 CAPLUS
DN 132:256034
TI 2-Methylthienobenzodiazepine formulation
IN Bunnell, Charles Arthur; Ferguson, Thomas Harry; Hendriksen, Barry Arnold;
Sanchez-Felix, Manuel Vicente; Tupper, David Edward
PA Eli Lilly and Company, USA

Applicants

SO PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000018408	A1	20000406	WO 1999-US6417	19990324

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1998-163768 19980930
US 1998-163769 19980930

AB The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates. Thus, olanzapine was prepd. and mixed with cholesterol in methylene chloride. An aq. soln. of PVA was added to the above soln. and the mixt. was passed through 100- and 230-mesh sieves, and the particles thus obtained were allowed to dry.

IT **132539-06-1P**, Olanzapine
RL: BPR (Biological process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(methylthienobenzodiazepine formulations)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



RE.CNT 1
(1) Cygnus Inc; WO 9709985 A1 1997 CAPLUS

L21 ANSWER 7 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1999:783941 CAPLUS
DN 132:9033
TI Combination therapy of atypical antipsychotics and serotonin reuptake

inhibitors for treatment of bipolar disorders
IN Tollefson, Gary Dennis
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9962522	A1	19991209	WO 1999-US11314	19990521
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9940088	A1	19991220	AU 1999-40088	19990521
EP 966967	A2	19991229	EP 1999-303968	19990521
EP 966967	A3	20000531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRAI US 1998-PV87126 19980529
US 1998-87126 19980529
WO 1999-US11314 19990521

AB The invention provides methods and compns. for the treatment of bipolar disorder, bipolar depression or unipolar depression, all with or without psychotic features. This method employs a compd. having activity as an atypical antipsychotic in combination with an effective amt. of a second compd. selected from the group consisting of a serotonin reuptake inhibitor, an anticonvulsant and lithium. Pharmaceutical formulations of combination of drugs of the invention are presented. E.g., hard gelatin capsules were prepd. contg. olanzapine 25 mg, fluoxetine-HCl 20 mg, starch 150 mg, and Mg stearate 10 mg. In a double blind trial in patients diagnosed with treatment-resistant major depression, the administration of fluoxetine plus olanzapine (20-60 mg/day and 5-20 mg/day, resp.) resulted in a greater improvement on the HAMD-21 score than either of the monotherapy.

IT **132539-06-1**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy for treatment of bipolar disorders)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



RE.CNT 10
(1) Anon; Chem abstr P1998 CAPLUS
(2) Anon; Chem abstr 1982 CAPLUS
(3) Anon; Chem abstr 1985 CAPLUS
(4) Anon; Chem abstr 1997 CAPLUS
(5) Anon; Chem abstr 1997 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 8 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1999:763863 CAPLUS
DN 132:6368
TI Compositions and methods employing R(-)fluoxetine and other active ingredients
IN Barberich, Timothy J.; Rubin, Paul D.; Handley, Dean A.
PA Sepracor Inc., USA
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9961014	A2	19991202	WO 1999-US11725	19990527

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1998-86262 19980528
AB Pharmaceutical compns. which comprise R(-) fluoxetine and one or more other biol. active compds. e.g. a benzodiazepine compd., a tricyclic antidepressant, a 5-HT1A receptor antagonist, a 5-HT3 receptor agonist, a .beta.-adrenergic antagonist, an antipsychotic agent, an anti-anxiolytic or other psychotropic drug, are disclosed. Methods of treating or preventing a disease or disorder, esp. a psychotic or psychiatric disease or disorder, using the above pharmaceutical compn. or by administering a R(-)fluoxetine in combination with one or more other biol. active compds. are also disclosed. Methods of treating patients having or at risk of having AIDS or HIV infection, cancer, cardiac disorder, post-myocardial

depression and post-traumatic stress disorder using optically pure R(-)fluoxetine in combination with one or more other biol. active compds. are further disclosed.

IT **132539-06-1**, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(psychotropic compns. contg. R(-)fluoxetine and other active compds.)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L21 ANSWER 9 OF 73 CAPLUS COPYRIGHT 2000 ACS

AN 1999:753081 CAPLUS

DN 131:346552

TI Combination of 5-HT3 receptor antagonist and serotonin reuptake inhibitor for treatment of depression

IN Michelson, David; Tollefson, Gary Dennis

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 25 pp.
CODEN: PIXXD2

DT **Patent**

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9959593	A1	19991125	WO 1999-US10092	19990510

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1998-86268 19980521

AB The present invention provides a method for treating a patient suffering from depression, comprising administering to said patient an effective amt. of a first component which is a 5-HT3 receptor antagonist, in combination with an effective amt. of a second component which is a serotonin reuptake inhibitor wherein improvement in sexual dysfunction and/or redn. in gastrointestinal side effects is recognized. Various

formulations were prepd. E.g., a tablet was prepd. using zatosetron 10, fluoxetine HCl 10, microcryst. cellulose 275, fumed silica 10, and stearic acid 5 mg, resp.

IT **132539-06-1**, Olanzapine
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(combination of 5-HT3 receptor antagonist and serotonin reuptake inhibitor for treatment of depression with reduced side effects)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



RE.CNT 7
(1) Anon; The Merck Index - 11th Edition 1989, P655
(2) Devane, C; American Journal of Psychiatry 1997, V154(9), P1317 MEDLINE
(4) Miller, D; Neuropsychopharmacology 1997, V17(4), P230 CAPLUS
(5) Miyata, K; Pharmacologica Japonica 1994, V104(3), P143 CAPLUS
(7) Weisler, R; Annals of Clinical Psychiatry 1997, V9(4), P259 MEDLINE
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 10 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1999:752863 CAPLUS
DN 131:346550
TI Atypical antipsychotic agent-serotonin reuptake inhibitor combinations for therapy of refractory depression
IN Tollefson, Gary Dennis
PA Eli Lilly and Co., USA
SO Eur. Pat. Appl., 15 pp.
CODEN: EPXXDW
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 958824	A2	19991124	EP 1999-303969	19990521
	EP 958824	A3	19991201		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

WO 9961027 A1 19991202 WO 1999-US11276 19990521
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRAI US 1998-86444 19980522
AB Methods and compns. are provided for the treatment of depressive states refractory to treatment with traditional antidepressive therapies alone. These methods and compns. employ a compd. having activity as an atypical antipsychotic (e.g. olanzapine) and a serotonin reuptake inhibitor (e.g. fluoxetine). This invention also provides methods of providing rapid onset treatments of major depression which employing a compd. having activity as an atypical antipsychotic and a serotonin reuptake inhibitor.
IT **132539-06-1P**, Olanzapine
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(atypical antipsychotic agent-serotonin reuptake inhibitor combinations
for therapy of refractory depression)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 11 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1999:672562 CAPLUS
DN 131:281590
TI Methods for treating neuropsychiatric disorders
IN Tsai, Guochuan; Coyle, Joseph
PA The General Hospital Corporation, USA
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9952519	A2	19991021	WO 1999-US8056	19990414

WO 9952519 A3 19991202
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 9935571 A1 19991101 AU 1999-35571 19990414
PRAI US 1998-PV81645 19980414
WO 1999-US8056 19990414

AB The invention provides methods for treating neuropsychiatric disorders such as schizophrenia, Alzheimer's Disease, autism, depression, benign forgetfulness, childhood learning disorders, close head injury, and attention deficit disorder. The methods entail administering to a patient with a neuropsychiatric disorder a pharmaceutical compn. contg. (i) a therapeutically effective amt. of D-alanine (or a modified form), provided that the compn. is substantially free of D-cycloserine, and/or (ii) D-serine (or a modified form), and/or (iii) 105 to 500 mg of D-cycloserine (or a modified form), and/or (iv) N-methylglycine (or a modified form). Using double-blind conditions, patients were randomly assigned to receive placebo (fruit juice), D-serine 30, D-alanine 60-100, or N-methylglycine 30 mg/kg/day once a day by mouth for 6 wk. Treatment with D-serine, D-alanine, or N-methylglycine improved the schizophrenic symptoms and cognitive deficit of the patients. Specifically, treatment with D-serine resulted in a 21% redn. of the neg. symptoms (on the SANS scale), and it resulted in a 17% redn. of the pos. symptoms. Treatment with D-alanine resulted in an 11% redn. of the neg. symptoms and a 12% redn. of the pos. symptoms. Reatment with N-methylglycine resulted in a 20% redn. of the neg. symptoms and a 15% redn. of the pos. symptoms. These redns. in the neg. and pos. symptoms represented clin. significant improvement.

IT **132539-06-1**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for treating neuropsychiatric disorders)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 12 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1999:659583 CAPLUS
DN 131:269054
TI Pharmacological MRI (PHRMI)
IN Jenkins, Bruce G.; Mandeville, Joe B.; Cavagna, Friedrich M.
PA The General Hospital Corporation, USA; Bracco S.P.A.
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9951994	A1	19991014	WO 1999-US7550	19990407
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9934743	A1	19991025	AU 1999-34743	19990407

PRAI US 1998-81048 19980408
WO 1999-US7550 19990407

AB A method for Magnetic Resonance Imaging (MRI) of changes in neurotransmitter and neuroreceptor activity as a metabolic response to diagnostic challenge or therapeutic treatment in a patient with suspected or already diagnosed mental illnesses of psychiatric, neurodegenerative or neurol. nature, comprising the steps of: a) administering to said patient a drug eliciting an MRI detectable hemodynamic response; b) administering to said patient an MRI contrast agent with high magnetic susceptibility and c) measuring, in a spatially and temporally resolved manner, relative Cerebral Blood Vol. (rCBV) changes assocd. to neuronal activation using T2- or T2*- weighted MRI scans at the equil. distribution of said contrast agent.

IT **132539-06-1**, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MRI of changes in neurotransmitter and neuroreceptor activity in

mental illnesses of psychiatric, neurodegenerative or neurol. nature)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine,
2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



RE.CNT 8
(1) Burdett, N; MAGNETIC RESONANCE IMAGING 1995, V13(4), P549 CAPLUS
(2) Ching, Y; MAGNETIC RESONANCE IN MEDICINE 1997, V38, P389
(5) Jones, R; NMR IN BIOMEDICINE 1997, V10, P59 MEDLINE
(6) Mandeville, J; MAGNETIC RESONANCE IN MEDICINE 1998, V39, P615 MEDLINE
(8) Silva, A; MAGNETIC RESONANCE IN MEDICINE 1995, V33, P209 MEDLINE
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 13 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1999:622281 CAPLUS
DN 131:237981
TI Treatment of presymptomatic Alzheimer's disease with NMDA antagonists to prevent neuronal degeneration
IN Olney, John W.; Farber, Nuri B.
PA Washington University, USA
SO U.S., 37 pp.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5958919	A	19990928	US 1996-710727	19960920

AB Methods for treating the very early (presymptomatic) stages of Alzheimer's disease are disclosed, wherein NMDA antagonist drugs are administered to protect NMDA receptors against neuronal damage. Since NMDA antagonists may cause a condition known as NMDA receptor hypofunction (NR/hypo) that triggers neurotoxic side effects, they may be co-administered with, or have inherent activity as, "safener" drugs to prevent toxic side effects. The patient's status must be monitored, so that any NMDA antagonist drugs can be discontinued if a condition of NR/hypo arises. Otherwise, the NMDA antagonist drugs can worsen and accelerate the damage caused by the disease. Eliprodil and ibogaine had NMDA antagonist activity in the chick retina assay. They also showed safener action mediated through sigma

receptors.

IT **132539-06-1**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(potency ranking of, as safener drug; treatment of presymptomatic Alzheimer's disease with NMDA antagonists to prevent neuronal degeneration)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RE.CNT 37
(2) Beal, M; Ann Neurol 1992, V31, P119 CAPLUS
(4) Bryson, H; Drugs and Aging 1997, V10, P234 CAPLUS
(8) Ellison, G; Brain Research Reviews 1995, V20, P250 CAPLUS
(9) Fonnum, F; Annals New York Acad Sci 1995, V757, P475 CAPLUS
(12) Gong, C; Brain Res 1996, V741, P95 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 14 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1999:425470 CAPLUS
DN 131:78439
TI Oral formulations containing olanzapine
IN Cochran, George Randall; Morris, Tommy Clifford
PA Eli Lilly and Company, USA
SO U.S., 7 pp., Cont.-in-part of U.S. Ser. No. 410,465, abandoned.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5919485	A	19990706	US 1996-716922	19960920
WO 9629995	A1	19961003	WO 1996-US3918	19960322
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2216372	AA	19961003	CA 1996-2216372	19960322
AU 9654280	A1	19961016	AU 1996-54280	19960322

	AU 696601	B2	19980917		
	GB 2313783	A1	19971210	GB 1997-19817	19960322
	GB 2313783	B2	19981118		
	DE 19681287	T	19980319	DE 1996-19681287	19960322
	CN 1179102	A	19980415	CN 1996-192778	19960322
	BR 9607791	A	19980707	BR 1996-7791	19960322
	AT 9609022	A	19990215	AT 1996-9022	19960322
	AT 405606	B	19991025		
	JP 11502848	T2	19990309	JP 1996-529533	19960322
	SE 9703206	A	19970905	SE 1997-3206	19970905
	LT 4350	B	19980525	LT 1997-149	19970916
	FI 9703749	A	19970922	FI 1997-3749	19970922
	NO 9704363	A	19971117	NO 1997-4363	19970922
	DK 9701090	A	19971112	DK 1997-1090	19970923
	LV 11983	B	19980720	LV 1997-199	19971014

PRAI US 1995-410465 19950324
WO 1996-US3918 19960322

AB The invention provides a pharmaceutically acceptable solid oral formulation of olanzapine and a process for making such formulation. A preferred formulation of the invention is a solid oral formulation comprising 1-20 mg olanzapine, wherein such solid oral formulation is coated with hydroxypropyl Me cellulose. The coating provides a phys. stability and effectively prevents the undesired discoloration phenomenon in the formulation.

IT **132539-06-1P**, Olanzapine
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Form II polymorph; polymer-coated oral formulations contg. olanzapine)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RE.CNT 4
(1) Anon; EP 582368 A1 1993
(2) Chakrabarti; US 4115568 1978
(3) Chakrabarti; US 5229382 1993
(4) Greenwood; US 5457101 1995 CAPLUS

L21 ANSWER 15 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1999:355752 CAPLUS
DN 131:719

TI A covalent conjugate of clozapine with a fatty acid and its use for treating schizophrenia
IN Bradley, Matthews O.; Shashoua, Victor E.; Swindell, Charles S.; Webb, Nigel L.
PA Neuromedica, Inc., USA
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9926661	A1	19990603	WO 1998-US24412	19981116
	W: AU, CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9914115	A1	19990615	AU 1999-14115	19981116

PRAI US 1997-978541 19971126
WO 1998-US24412 19981116

AB The invention provides compns. that include conjugates of a fatty acid mol., preferably cis-docosahexaenoic acid, and clozapine. The conjugates are useful in treating psychol. disorders such as schizophrenia. Docosahexaenoic acid-clozapine (prepn. given) was at least six times longer-acting than clozapine against locomotor behavioral arousal in rats treated with R(-) apomorphine.

IT **132539-06-1**, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical further contg.; clozapine conjugate with fatty acid for
treating schizophrenia)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



RE.CNT 4
(1) Marder, S; Journal of Clinical Psychiatry 1996, V57(Suppl 03), P9
(2) Scotia Holdings PLC; EP 0599576 A 1994
(3) Shashoua, V; US 4939174 A 1990
(4) Stowell, M; WO 9817325 A 1998

L21 ANSWER 16 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1999:344848 CAPLUS

DN 131:714
TI Therapeutic uses of triazolo-pyridazine derivatives
IN Castro Pineiro, Jose Luis; Hefti, Franz Fridolin; Hill, Raymond George; McKernan, Ruth; Tattersall, Frederick David; Whiting, Paul John
PA Merck Sharp & Dohme Limited, UK
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9925353	A1	19990527	WO 1998-GB3328	19981106
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9910415	A1	19990607	AU 1999-10415	19981106
	US 6046196	A	20000404	US 1998-208291	19981209
	US 6063783	A	20000516	US 1998-209071	19981210

PRAI GB 1997-23999 19971113
GB 1997-26699 19971218
GB 1997-26700 19971218
GB 1997-26701 19971218
GB 1997-26702 19971218
GB 1998-1581 19980123
WO 1998-GB3328 19981106
OS MARPAT 131:714
AB A class of substituted or 7,8-ring fused 1,2,4-triazolo[4,3-b]pyridazine derivs., possessing an optionally substituted cycloalkyl, Ph or heteroaryl substituent at the 3-position and a substituted alkoxy moiety at the 6-position, are selective ligands for GABAA receptors, in particular having high affinity for the .alpha.2 and/or .alpha.3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders including schizophrenia; neurodegeneration arising from cerebral ischemia; pain; emesis; and muscle spasm or spasticity, e.g. in paraplegic patients.
IT **132539-06-1**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(triazolo-pyridazine deriv. GABAA ligands and therapeutic use, alone or with other compds.)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



RE.CNT 13
(1) Anon; S-TRIAZOLO(3,4-a) (5, 6, 7, 8)TETRAHYDROPHTHA LAZINES 1978, 5, CAPLUS
(2) Delini-Stula, A; JOURNAL OF PSYCHIATRIC RESEARCH 1996, V30(4), P239 MEDLINE
(4) Hadingham, K; MOLECULAR PHARMACOLOGY 1993, V43, P970 CAPLUS
(5) Hall, E; JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM 1997, V17(8), P875 CAPLUS
(13) Tarzia, G; FARMACO EDIZIONE SCIENTIFICA 1988, V43(2), P189 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 17 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1999:316595 CAPLUS
DN 130:320861
TI Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
IN Olney, John W.; Farber, Nuri B.
PA Washington University, USA
SO U.S., 22 pp.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5902815	A	19990511	US 1996-709222	19960903

AB This invention relates to a new method for treating or preventing brain damage caused by NMDA receptor hypofunction (NR/hypo), using drugs such as lisuride which stimulate (agonize) activity at the 5HT-2A class of serotonin receptors, but which do not cause hallucinations. Data disclosed herein indicate that stimulation of both 5HT-2A and 5HT-2C receptors causes hallucinations, while stimulation of 5HT-2A receptors but not 5HT-2C receptors does not. Accordingly, to be useful herein, non-hallucinatory 5HT-2A agonists should either (1) antagonize (suppress) activity at 5HT-2C receptors, or (2) have no significant effect on activity at 5HT-2C receptors. Selective non-hallucinatory 5HT-2A agonists can be used in either of two treatment methods disclosed herein. One such treatment comprises administering a 5HT-2A receptor agonist as a "safener drug" which accompanies an NMDA antagonist drug that is being used for a

therapeutic purpose. Another method disclosed herein involves the use of a 5HT-2A agonist drug, by itself, to combat a naturally-occurring form of NMDA receptor hypofunction which occurs in people suffering from schizophrenia. Although 5HT-2A agonists would not be optimally effective in treating long-standing cases of chronic schizophrenia, where pathol. changes in the brain have already reached maximal or severe levels, 5HT-2A agonists can be administered early in the illness, such as at the first signs of schizophrenic illness, and continuously thereafter to prevent the development or worsening of pathol. brain dysfunction and the resulting psychosis.

IT **132539-06-1**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(serotonin 5HT-2A agonists for prevention of adverse effects of NMDA receptor hypofunction)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



RE.CNT 20
(1) Caldwell, M; Neuropsychobiology 1996, V34, P117 CAPLUS
(3) Carlsson, M; Journal of Neural Transmission 1995, V100, P225 CAPLUS
(5) Fink, H; Psychoparmacology 1985, V85, P464 CAPLUS
(6) Fiorella, D; Psychoparmacology 1995, V121, P357 CAPLUS
(7) Glennon, R; Neuropsychopharmacology 1990, V3, P509 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 18 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1999:316525 CAPLUS
DN 130:343012
TI Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
IN Chen, Tung-fen; Chiang, Chia-ming; Jona, Janan; Joshi, Priti; Ramdas, Asha
PA Cygnus, Inc., USA
SO U.S., 15 pp., Cont.-in-part of U.S. Ser. No. 581,128, abandoned.
CODEN: USXXAM
DT **Patent**
LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5902603	A	19990511	US 1996-713711	19960913
PRAI	US 1995-528105	19950914			
	US 1995-581128	19951229			

AB High capacity drug reservoirs are provided for incorporation into transdermal drug delivery systems. The drug reservoirs are hydrogels formulated from polyurethanes crosslinked with diisocyanate crosslinking agents or cured with radiation in the presence of a photoinitiator. Drug loading as high as 65 to 70 % or higher can be achieved by absorbing drug formulation into the reservoir after hydrogel synthesis. Methods for making and using transdermal systems contg. such reservoirs are provided as well. Olanzapine was dissolved in a combination of vehicles contg. Me laurate 10, lauryl lactate 45, and 1,2-butanediol 45 %, added with water to Hypol PreMA G-50 polymer (Hampshire Chem. Corporation) (the ratio of water to polymer was approx. 2:1) and mixed together until a hydrogel was formed. The gel was cut into circles and applied onto human cadaver skin using a Franz diffusion cell and at predetd. times, the receiver fluid was replaced with fresh fluid and analyzed for olanzapine using HPLC.

IT **132539-06-1**, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyurethane hydrogel reservoirs for steroid transdermal delivery systems contg. permeation enhancers)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



RE.CNT 16
(1) Anon; WO 91/05809 1991 CAPLUS
(2) Anon; WO 92/20324 1992 CAPLUS
(4) Anon; WO 97/09971 1997 CAPLUS
(5) Anon; WO 97/24148 1997 CAPLUS
(8) Cartmell; US 5160328 1992 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 19 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1999:297269 CAPLUS
DN 130:332902
TI Treatment of schizophrenia with AMPAkines and neuroleptics
IN Johnson, Steven A.; Rogers, Gary A.; Lynch, Gary S.

PA Cortex Pharmaceuticals, Inc., USA; The Regents of the University of California
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9921422	A1	19990506	WO 1998-US22707	19981026
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9913658	A1	19990517	AU 1999-13658	19981026

PRAI US 1997-63627 19971027
WO 1998-US22707 19981026
OS MARPAT 130:332902
AB The invention relates to treatment of schizophrenia and related psychotic disorders, including enhancement of receptor functioning in synapses in brain networks responsible for higher order behaviors. In a particular aspect, the invention relates to methods for the use of AMPA receptor up-modulators in conjunction with antipsychotics for the treatment of schizophrenia. Kits contg. the compns. in appropriate form for administration are also provided. A representative AMPAkine (CX516) synergistically enhanced clozapine antagonism of methamphetamine-induced rearing activity.
IT **132539-06-1**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(AMPAkines and antipsychotic agents for treatment of schizophrenia)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



RE.CNT 2
(1) The Regents Of The University Of California; WO 9707799 A1 1997 CAPLUS

(2) Vanover, K; Eur J Pharmacol 1997, V332(2), P115 CAPLUS

L21 ANSWER 20 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1999:282129 CAPLUS
DN 130:291604
TI Methods of screening potential atypical antipsychotic drugs
IN Wang, Rex Y.; Liang, Xiaofu
PA The Research Foundation of State University of New York, USA
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9920315	A1	19990429	WO 1998-US22492	19981023
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9911180	A1	19990510	AU 1999-11180	19981023
PRAI	US 1997-62750		19971023		
	WO 1998-US22492		19981023		

AB Methods are disclosed for screening potential atypical antipsychotic drugs (APDs). One method comprises examn. of the ability of potential APDs to prevent the N-methyl-D-aspartate (NMDA) receptor antagonist phencyclidine (PCP)-induced blockade of NMDA responses in pyramidal cells of the medial prefrontal cortex in in vitro brain slice prepns. Another method disclosed herein involves examn. of the ability of potential atypical APDs to prevent effects produced by repeated treatment of PCP in pyramidal cells of the medial prefrontal cortex in in vitro brain slice prepns. In humans, not only does PCP causes hallucinations and delusions, but it also causes an assocd. apathetic state and a type of formal thought disorder that are distinctive features of schizophrenia. Furthermore, in schizophrenics, NMDA antagonists produce an exacerbation of psychotic symptoms and cognitive impairment. Cognitive deficits have also been obsd. in PCP-treated rats and monkeys. Evidence has been accumulating to show that atypical APDs are a lot more effective than typical APDs in preventing/reversing the PCP-induced effect. Electrophysiol. methods are disclosed herein for screening potential atypical APDs and predicting their therapeutic efficacy in schizophrenic neg. symptoms and neuropsychol. and cognitive deficits.

IT **132539-06-1**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(screening potential atypical antipsychotic drugs)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



RE.CNT 9
(1) Church; Neuroscience Letters 1991, V124, P232 CAPLUS
(2) Corbett; Psychopharmacology 1995, V120, P67 CAPLUS
(3) Hoffman; Psychopharmacology 1993, V111, P339 CAPLUS
(4) Malouf; Neuropharmacology 1988, V27(11), P1161 CAPLUS
(5) McQuiston; Neuroscience Letters 1992, V138, P261 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 21 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1999:233762 CAPLUS
DN 130:257362
TI Methylthienobenzodiazepine derivative antipsychotic drug formulation.
IN Allen, Douglas James; Dekemper, Kurt Douglas; Ferguson, Thomas Harry; Garvin, Stuart James; Murray, Linda Cameron; Brooks, Norman Dale; Bunnell, Charles Arthur; Hendriksen, Barry Arnold; Mascarenhas, Snehlata Singh; Shinkle, Sharon Louise; Sanchez-Felix, Manuel Vicente; Tupper, David Edward
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9916313	A1	19990408	WO 1998-US20426	19980930
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9895914	A1	19990423	AU 1998-95914	19980930

PRAI US 1997-60493 19970930
WO 1998-US20426 19980930

AB The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2.3-b][1.5]benzodiazepine (olanzapine) (prepn. given) or olanzapine pamoate or solvates thereof. The invention further provides

novel olanzapine pamoate salts or solvates thereof.

IT **132539-06-1P**, Olanzapine
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and formulation of)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RE.CNT 2
(1) Beasley Jr; US 5602897 A 1997
(2) Chakrabarti; US 5229382 A 1993

L21 ANSWER 22 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1999:233761 CAPLUS
DN 130:276761
TI Method for treating sexual dysfunction using 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine
IN Tran, Pierre Van
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9916312	A1	19990408	WO 1998-US20152	19980925
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9895834	A1	19990423	AU 1998-95834	19980925
EP 911028	A2	19990428	EP 1998-307950	19980930
EP 911028	A3	19990506		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI US 1997-60415		19970930		
WO 1998-US20152		19980925		

AB The invention provides a method for treating a sexual dysfunction comprising administering an effective amt. of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine. Prepn. of the compd. of the invention is described, and pharmaceutical compns. are included.

IT **132539-06-1D**, form I
RL: BAC (Biological activity or effector, except adverse); FMU (Formation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
(thienobenzodiazepine deriv. for sexual dysfunction treatment, prepn., and compns.)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(thienobenzodiazepine deriv. for sexual dysfunction treatment, prepn., and compns.

RE.CNT 1

(1) Beasley; US 5817657 A 1998 CAPLUS

L21 ANSWER 23 OF 73 CAPLUS COPYRIGHT 2000 ACS

AN 1999:194003 CAPLUS

DN 130:227755

TI Controlled-release microsphere delivery system comprising a drug and a fatty acid

IN Illum, Lisbeth; Cheng, Yu-hui; Watts, Peter James; Davis, Stanley Stewart

PA Danbiosyst UK Ltd., UK

SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2

DT **Patent**

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9912549	A2	19990318	WO 1998-GB2692	19980907
	WO 9912549	A3	19990506		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,

NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9889925 A1 19990329 AU 1998-89925 19980907
PRAI GB 1997-18986 19970909
WO 1998-GB2692 19980907

AB A pharmaceutical compn. comprises polymeric microparticles including a drug and a fatty acid, which compn. may be adapted to provide a release rate of drug that is approx. linear with time, and to provide no significant burst effect. Olanzapine (I) 200, oleic acid 50, and poly(lactide-glycolide) 400 mg were dissolved in 4 mL dichloromethane to form an oil phase. The oil phase was dropped into 200 mL of cooled aq. phase contg. 1% polyvinyl alc. and emulsified and the resultant emulsion was agitated continuously for 4 h at room temp. The microspheres thus obtained were collected, freeze-dried and passed through a 250 .mu.m sieve to remove any larger aggregation. There was almost no burst effect and the release profile of I was essentially linear over a 10 day period.

IT **132539-06-1**, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled-release microsphere delivery system comprising drug and fatty acid)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 24 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1999:147369 CAPLUS
DN 130:177544
TI Preventing neuronal degeneration in Alzheimer's disease with clozapine, olanzapine and fluperlapine, and salts, isomers and analogs thereof
IN Olney, John W.; Farber, Nuri B.
PA Washington University, USA
SO U.S., 32 pp.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI	US 5877173	A	19990302	US 1996-704093	19960828

AB A method for reducing progressive neuronal degeneration due to Alzheimer's disease is disclosed wherein a neuroprotective drug selected from the group consisting of clozapine, olanzapine and fluperlapine, and salts, isomers and analogs thereof, is administered.

IT **132539-06-1**, Olanzapine **132539-06-1D**, Olanzapine, analogs and isomers
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(clozapine, olanzapine, and fluperlapine, and salts, isomers, and analogs thereof, for prevention of neuronal degeneration in Alzheimer's disease)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



RE.CNT 30
(2) Bryson, H; Drugs and Aging 1997, V10, P234 CAPLUS

(6) Ellison, G; Brain Research Reviews 1995, V20, P250 CAPLUS
(8) Gong, C; Brain Res 1996, V741, P95 CAPLUS
(12) Marx, J; Science 1996, V273, P50 CAPLUS
(13) Mattson, M; Neurobiology of Aging 1995, V16, P447 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 25 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1998:708815 CAPLUS
DN 129:335734
TI Pharmaceutical compositions containing olanzapine for treatment of amyotrophic lateral sclerosis
IN Bymaster, Franklin Porter; Tollefson, Gary Dennis
PA Eli Lilly and Co., USA
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9846596	A1	19981022	WO 1998-US6932	19980408
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9869559	A1	19981111	AU 1998-69559	19980408
	EP 872238	A2	19981021	EP 1998-302789	19980409
	EP 872238	A3	19981028		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1997-43094	19970415			
	WO 1998-US6932	19980408			

AB Pharmaceutical compns. for treating amyotrophic lateral sclerosis and for providing a neuro-protective effect comprise administering a therapeutically effective of olanzapine (I) or a pharmaceutically acceptable salt or solvate thereof. A suspension of I (prepn. given) in Et acetate was heated at 76.degree. for 30 min., then it was allowed to cool to 25.degree.. Form II I which was isolated by filtration had potency .gtoreq.97%. Formulation of a tablet contg. I was given.
IT **132539-06-1P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pharmaceutical compns. contg. olanzapine for treatment of amyotrophic lateral sclerosis)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 26 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1998:706091 CAPLUS
DN 129:298403
TI Method for treating cerebral focal stroke with olanzapine
IN Bymaster, Franklin Porter; Tollefson, Gary Dennis
PA Eli Lilly and Co., USA
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9846230	A1	19981022	WO 1998-US7154	19980408
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9868961	A1	19981111	AU 1998-68961	19980408
	EP 872239	A2	19981021	EP 1998-302794	19980409
	EP 872239	A3	19981028		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRAI US 1997-43095 19970415
WO 1998-US7154 19980408 no US

AB A method is provided for treating cerebral focal stroke comprising administering a therapeutically effective dosage of olanzapine or a pharmaceutically acceptable salt or solvate thereof. Prepn. of form II olanzapine polymorph is described.

IT **132539-06-1DP**, Olanzapine, form II polymorph
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(olanzapine for cerebral focal stroke treatment)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



IT **132539-06-1P**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(olanzapine for cerebral focal stroke treatment)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 27 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1998:682129 CAPLUS
DN 129:286011
TI New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
IN Broekkamp, Christophorus Louis Eduard; Berendsen, Hermanus Henricus Gerardus; Pinder, Roger Martin
PA Akzo Nobel N.V., Neth.
SO PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9843646	A1	19981008	WO 1998-EP1920	19980325

W: AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

ZA	9802368	A	19980923	ZA 1998-2368	19980319
AU	9872139	A1	19981022	AU 1998-72139	19980325
EP	969845	A1	20000112	EP 1998-919209	19980325

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

NO	9904673	A	19991117	NO 1999-4673	19990924

PRAI EP 1997-200881 19970327
EP 1997-202785 19970911
WO 1998-EP1920 19980325

AB Therapeutic combinations of mirtazapine and an antipsychotic agent are disclosed, as are pharmaceutical compns. contg. these combinations and their use in the treatment or prophylaxis of psychotic disorders.

IT **132539-06-1**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mirtazapine-antipsychotic agent combinations for treatment or prophylaxis of psychotic disorders)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 28 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1998:653544 CAPLUS
DN 129:286009
TI 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine for treatment of psychoactive substance disorders
IN Beasley, Charles M., Jr.; Chakrabarti, Jiban Kumar; Hotten, Terrence Michael; Tupper, David Edward
PA Eli Lilly and Company, USA; Eli Lilly and Company Limited
SO U.S., 10 pp. Cont.-in-part of U.S. 5,605,897.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5817657	A	19981006	US 1996-748294	19961113
	US 5229382	A	19930720	US 1992-890348	19920522
	US 5605897	A	19970225	US 1995-387498	19950213
PRAI	US 1991-690143	19910423			
	US 1992-890348	19920522			
	US 1993-44844	19930408			
	US 1995-387498	19950213			
	GB 1990-9229	19900425			

AB 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine (prepn. described), or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders relating to the use of psychoactive substances.

IT **132539-06-1P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(methyl(methylpiperazinyl)thienobenzodiazepine, prepn., pharmaceutical formulations, and treatment of psychoactive substance disorders)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L21 ANSWER 29 OF 73 CAPLUS COPYRIGHT 2000 ACS

AN 1998:653543 CAPLUS

DN 129:286008

TI 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine for treatment of mental disorders

IN Beasley, Charles M., Jr.; Chakrabarti, Jiban Kumar; Hotten, Terrence Michael; Tupper, David Edward

PA Eli Lilly and Company, USA; Eli Lilly and Company Limited

SO U.S., 10 pp. Cont.-in-part of U.S. 5,605,897.
CODEN: USXXAM

DT **Patent**

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5817656	A	19981006	US 1996-748293	19961113
	US 5229382	A	19930720	US 1992-890348	19920522

US 5605897 A 19970225 US 1995-387498 19950213
PRAI US 1991-690143 19910423
US 1992-890348 19920522
US 1993-44844 19930408
US 1995-387498 19950213
GB 1990-9229 19900425
AB 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine (prepn. described), or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of mental disorders.
IT **132539-06-1P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(methyl(methylpiperazinyl)thienobenzodiazepine, prepn., pharmaceutical formulations, and use for treatment of mental disorders)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 30 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1998:653542 CAPLUS
DN 129:270629
TI Methods of treatment of psychotic conditions using a thieno-benzodiazepine
IN Chakrabarti, Jiban Kumar; Hotten, Terrence Micharl; Tupper, David Edward
PA Eli Lilly and Company, USA; ELI LILLY AND COMPANY LIMITED
SO U.S., 10 pp. Cont.-in-part of U.S. 5,627,178.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5817655	A	19981006	US 1996-748292	19961113
US 5229382	A	19930720	US 1992-890348	19920522
US 5627178	A	19970506	US 1995-387997	19950213
US 6008216	A	19991228	US 1998-122294	19980724
PRAI US 1991-690143	19910423			
US 1992-890348	19920522			
US 1993-44844	19930408			

US 1995-387997 19950213
GB 1990-9229 19900425
US 1996-748292 19961113

AB 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine (I), or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system. The results of pharmacol. tests show that I (prepn. given) is an antagonist of dopamine at D-1 and D-2 receptors, has antimuscarinic anticholinergic properties, and antagonist activity at 5HT-2 receptor sites. It also has antagonist activity at noradrenergic .alpha.-receptors. Overall in clin. situations, I showed marked superiority and a better side effects profile than prior art antipsychotic agents, and had a highly advantageous activity level.

IT **132539-06-1P**
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(treatment of psychotic conditions using thieno-benzodiazepine compd.)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of psychotic conditions using thieno-benzodiazepine compd.

L21 ANSWER 31 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1998:603230 CAPLUS
DN 129:207225
TI Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents
IN Audett, Jay; Bailey, Susan E.
PA Cygnus, Inc., USA
SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9837870	A1	19980903	WO 1998-US3832	19980227

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,

DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

CA 2252772	AA	19980903	CA 1998-2252772	19980227
AU 9866709	A1	19980918	AU 1998-66709	19980227
EP 910353	A1	19990428	EP 1998-908760	19980227

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

PRAI US 1997-808211 19970228 5,879,701
WO 1998-US3832 19980227

AB Solubilization enhancer compns. are provided which facilitate transdermal administration of basic drugs from transdermal systems composed of nonpolar adhesive materials. Preferred solubilization enhancer compns. are comprised of liq., isomeric acid mixts. such as oleic acid dimer. The invention also relates to novel transdermal systems, drug reservoirs, formulations, and methods of drug administration, in which the disclosed solubilization enhancer compns. are used. Good skin flux was obsd. during 2 days with a compn. contg. 2% tamsulosin, 2% lauric acid, 15% silica gel, 81% polyisobutylene at a 35 mg/cm2 coating wt., and 25% 1,3-butanediol-propylene glycol monolaurate 90 (9.5:0.5).

IT **132539-06-1**, Olanzapine
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizers)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 32 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1998:263237 CAPLUS
DN 128:312930
TI Olanzapine for treating insomnia
IN Tran, Pierre Van

PA Eli Lilly and Company, USA
SO U.S., 6 pp.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5744470	A	19980428	US 1997-799052	19970210

AB The invention provides a method for treating insomnia comprising administering an effective amt. of olanzapine to an elderly patient who has been previously treated with a hypnotic agent. 2-Methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-amine.cntdot.HCl was treated with N-methylpiperazine to obtain olanzapine, which was suspended in anhyd. EtOAc while heating and the product was isolated using vacuum filtration. The product was identified as Form II using x-ray powder anal. A tablet was formulated contg. 1.18 % olanzapine.
IT **132539-06-1P**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(olanzapine for treating insomnia)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 33 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1998:263236 CAPLUS
DN 129:8586
TI Method for treating dermatitis
IN Tran, Pierre V.
PA Eli Lilly and Company, USA
SO U.S., 4 pp.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5744469	A	19980428	US 1996-756996	19961126

AB The invention provides a method for treating fungal dermatitis comprising

administering an effective amt. of 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (I) to a patient in need thereof. I was prepd. from 2-methyl-4-amino-10H-thieno[2,3-b][1,5]benzodiazepine-HCl and N-methylpiperazine. Tablets contg. I were prepd.

IT **132539-06-1P**
RL: PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(piperazinyl thienobenzodiazepine deriv. for fungal dermatitis treatment)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L21 ANSWER 34 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1998:226721 CAPLUS
DN 128:261935
TI Olanzapine polymorph crystal form pharmaceutical
IN Bunnell, Charles Arthur; Hendriksen, Barry Arnold; Larsen, Samuel Dean
PA Eli Lilly and Company, USA
SO U.S., 8 pp. Cont.-in-part of U.S. Ser. No. 409,566, abandoned.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5736541	A	19980407	US 1996-686989	19960725
	CA 2214005	AA	19961003	CA 1996-2214005	19960322
	WO 9630375	A1	19961003	WO 1996-US3917	19960322
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9652578	A1	19961016	AU 1996-52578	19960322
	AU 9654279	A1	19961016	AU 1996-54279	19960322
	AU 706471	B2	19990617		
	GB 2313835	A1	19971210	GB 1997-19819	19960322

	GB 2313835	B2	19980916		
	DE 19681286	T	19980402	DE 1996-19681286	19960322
	CN 1179160	A	19980415	CN 1996-192775	19960322
	BR 9607790	A	19980707	BR 1996-7790	19960322
	JP 11502535	T2	19990302	JP 1996-529532	19960322
	AT 9609021	A	20000115	AT 1996-9021	19960322
	SE 9703205	A	19970905	SE 1997-3205	19970905
	LV 12018	B	19980920	LV 1997-163	19970908
	LT 4349	B	19980525	LT 1997-148	19970916
	FI 9703750	A	19970922	FI 1997-3750	19970922
	NO 9704365	A	19970922	NO 1997-4365	19970922
	DK 9701089	A	19971112	DK 1997-1089	19970923

PRAI US 1995-409566 19950324
US 1995-410474 19950324
WO 1996-US3854 19960322
WO 1996-US3917 19960322

AB The invention provides Form II, a pharmaceutically elegant, stable polymorph of olanzapine, useful for treating psychotic conditions, mild anxiety and gastrointestinal conditions.

IT **132539-06-1**, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(form II; olanzapine polymorph crystal form pharmaceutical)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L21 ANSWER 35 OF 73 CAPLUS COPYRIGHT 2000 ACS

AN 1998:204464 CAPLUS

DN 128:275100

TI Intermediates and process for preparing olanzapine

IN Bunnell, Charles Arthur; Larsen, Samuel Dean; Nichols, John Richard; Reutzel, Susan Marie; Stephenson, Gregory Alan

PA Eli Lilly and Co., USA

SO Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW

DT **Patent**

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 831098	A2	19980325	EP 1997-307383	19970922

EP 831098 A3 19980429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
WO 9812199 A1 19980326 WO 1997-US16499 19970918
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
AU 9744841 A1 19980414 AU 1997-44841 19970918
BR 9712100 A 19990831 BR 1997-12100 19970918
CN 1234802 A 19991110 CN 1997-198137 19970918
US 6020487 A 20000201 US 1997-935884 19970923
NO 9901382 A 19990322 NO 1999-1382 19990322
PRAI US 1996-26487 19960923
WO 1997-US16499 19970918
AB The present invention provides a process for prepg. olanzapine and dihydrate polymorphs. Olanzapine was prepd. from a known intermediate and later converted to its dihydrate. The x-ray powder anal. of the compd. was carried out.
IT **132539-06-1P**, Olanzapine
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(intermediates and process for prepg. olanzapine)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 36 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1998:204418 CAPLUS
DN 128:261967
TI Formulation comprising coated olanzapine particles
IN Morris, Tommy Clifford; Lange, Hans Joerg
PA Eli Lilly and Co., USA
SO Eur. Pat. Appl., 10 pp.
CODEN: EPXXDW
DT **Patent**
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 830858	A1	19980325	EP 1997-307380	19970922
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	WO 9813027	A1	19980402	WO 1997-US16547	19970918
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9744230	A1	19980417	AU 1997-44230	19970918
	CN 1230883	A	19991006	CN 1997-198099	19970918
	NO 9901405	A	19990323	NO 1999-1405	19990323
PRAI	US 1996-PV26633	19960924			
	WO 1997-US16547	19970918			

US eq.

AB A pharmaceutically elegant solid oral formulation comprising olanzapine as an active ingredient with one or more pharmaceutically acceptable excipients is provided, wherein the olanzapine is coated with cetyl alc., cetyl esters wax, carnauba wax, shellac, beeswax, magnesium stearate, hydroxypropyl Me cellulose, hydroxyethyl cellulose, Me hydroxyethyl cellulose, sodium CM-cellulose, hydroxypropyl cellulose, PVP, dimethylaminoethyl methacrylate-Me acrylate copolymer, Et acrylate-Me methacrylate copolymer, Me cellulose, and/or Et cellulose, to prevent dissolvation of olanzapine. Olanzapine is substantially pure form II polymorph (x-ray powder diffraction pattern is shown).

IT **132539-06-1**, Olanzapine
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(coated olanzapine particles for prevention of color changes in solid oral dosage forms)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L21 ANSWER 37 OF 73 CAPLUS COPYRIGHT 2000 ACS

AN 1998:98347 CAPLUS
DN 128:176168
TI Pharmaceutical compositions containing a 5-HT2C antagonist and a D2 antagonist for treatment of CNS disorders, including schizophrenia, and compound preparation
IN Blackburn, Thomas Paul
PA Smithkline Beecham PLC, UK; Blackburn, Thomas Paul
SO PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9804289	A2	19980205	WO 1997-EP4159	19970722
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9742972	A1	19980220	AU 1997-42972	19970722
	EP 936924	A2	19990825	EP 1997-918947	19970722
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI				
	CN 1230894	A	19991006	CN 1997-197977	19970722
	ZA 9706593	A	19990125	ZA 1997-6593	19970724
	NO 9900322	A	19990324	NO 1999-322	19990125

PRAI GB 1996-15767 19960726
WO 1997-EP4159 19970722

AB Combinations of compds. having 5-HT2C and D2 antagonist activity, compds. having activity at the two receptors, pharmaceutical compns. contg. them, and their use in treating CNS disorders, including schizophrenia, are disclosed.

IT **132539-06-1**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(D2 antagonist and 5-HT2C antagonist for treatment of CNS disorders, including schizophrenia, and compd. prepn.)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 38 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1997:650274 CAPLUS
DN 127:288191
TI Method for treating pain
IN Shannon, Harlan E.; Womer, Daniel E.
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9735586	A1	19971002	WO 1997-US4721	19970324
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2250187	AA	19971002	CA 1997-2250187	19970324
	AU 9725430	A1	19971017	AU 1997-25430	19970324
	CN 1219877	A	19990616	CN 1997-194951	19970324
	EP 921802	A1	19990616	EP 1997-916947	19970324
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
	BR 9708254	A	19990803	BR 1997-8254	19970324
	US 5945416	A	19990831	US 1997-823461	19970324
	NO 9804431	A	19981119	NO 1998-4431	19980923

PRAI US 1996-14128 19960325
US 1996-14129 19960325
US 1996-14130 19960325
US 1996-14132 19960325
WO 1997-US4721 19970324

AB The present invention provides a method for treating pain using a compn. comprising olanzapine and drug useful in the treatment of pain e.g. nonsteroidal antiinflammatories such as aspirin, indomethacin and ibuprofen.

IT **132539-06-1**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)
(method for treating pain with olanzapine and nonsteroidal antiinflammatories)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L21 ANSWER 39 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1997:650273 CAPLUS
DN 127:288190
TI Anesthetic method
IN Benvenga, Mark J.; Shannon, Harlan E.
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9735585	A1	19971002	WO 1997-US4720	19970324
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2250155	AA	19971002	CA 1997-2250155	19970324
	AU 9725429	A1	19971017	AU 1997-25429	19970324
	EP 904083	A1	19990331	EP 1997-916946	19970324
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
	US 5972932	A	19991026	US 1997-823459	19970324
PRAI	US 1996-14120	19960325			
	WO 1997-US4720	19970324			

AB The present invention provides a method for providing anesthesia using a compn. comprising olanzapine and one or more opioids.

IT **132539-06-1**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)
(anesthesia using a compn. comprising olanzapine and opioids.)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine,
2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 40 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1997:650271 CAPLUS
DN 127:298752
TI Olanzapine for treatment of pain
IN Helton, David R.; Kallman, Mary J.; Shannon, Harlan E.; Womer, Daniel E.
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9735583	A1	19971002	WO 1997-US4626	19970324
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2248873	AA	19971002	CA 1997-2248873	19970324
	AU 9723408	A1	19971017	AU 1997-23408	19970324
	EP 910381	A1	19990428	EP 1997-916159	19970324
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CN 1219878	A	19990616	CN 1997-194952	19970324
	BR 9708246	A	19990727	BR 1997-8246	19970324
	NO 9804446	A	19981125	NO 1998-4446	19980924
PRAI	US 1996-14131	19960325			
	US 1996-14133	19960325			
	US 1996-14153	19960325			
	WO 1997-US4626	19970324			

AB The present invention provides a method for treating pain comprising

administering an analgesic dosage of olanzapine or its polymorph. Olanzapine was prepd. by reaction of 2-methyl-4-amino-10H-thieno[2,3-b][1,5]-benzodiazepine with N-methylpiperazine in DMSO. Olanzapine tablets were prepd. by using a coating soln. of 10% HPMC.

IT **132539-06-1P**, Olanzapine
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(analgesic compns. contg. olanzapine)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L21 ANSWER 41 OF 73 CAPLUS COPYRIGHT 2000 ACS

AN 1997:650270 CAPLUS

DN 127:298751

TI Method for treating migraine pain

IN Shannon, Harlan E.; Womer, Daniel E.

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2

DT **Patent**

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9735582	A1	19971002	WO 1997-US4471	19970324
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2250186	AA	19971002	CA 1997-2250186	19970324
	AU 9725845	A1	19971017	AU 1997-25845	19970324
	CN 1219876	A	19990616	CN 1997-194950	19970324
	BR 9708145	A	19990727	BR 1997-8145	19970324
	US 5929070	A	19990727	US 1997-823457	19970324
	EP 932407	A1	19990804	EP 1997-917556	19970324
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				

SI, LT, LV, FI, RO
NO 9804432 A 19981124 NO 1998-4432 19980923
PRAI US 1996-14127 19960325
WO 1997-US4471 19970324
AB The present invention provides a method for treating migraine pain comprising administering an analgesic dosage of olanzapine. Olanzapine was prepd. and a polymorphic form prepd. and characterized. Tablet formulations were given.
IT **132539-06-1P**, Olanzapine
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(olanzapine compns. for treatment of migraine pain)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 42 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1997:632496 CAPLUS
DN 127:268052
TI Olanzapine for the treatment of insomnia
IN Van Tran, Pierre
PA Lilly, Eli, and Co., USA
SO Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 795330	A1	19970917	EP 1997-301534	19970307
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
ZA 9701899	A	19980907	ZA 1997-1899	19970305
CA 2248758	AA	19970918	CA 1997-2248758	19970307
WO 9733587	A1	19970918	WO 1997-US3592	19970307
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,				

GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9721989	A1	19971001	AU 1997-21989	19970307
CN 1212627	A	19990331	CN 1997-192796	19970307
BR 9708181	A	19990727	BR 1997-8181	19970307
JP 2000506528	T2	20000530	JP 1997-532707	19970307
NO 9804190	A	19980911	NO 1998-4190	19980911

PRAI US 1996-PV13126 19960311
GB 1996-6731 19960329
WO 1997-US3592 19970307

5,744,470

AB The invention discloses the use of olanzapine for treating insomnia. The prepn. and polymorphic form of olanzapine were given and tablets were prepd.

IT **132539-06-1P**, Olanzapine
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(olanzapine for the treatment of insomnia)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L21 ANSWER 43 OF 73 CAPLUS COPYRIGHT 2000 ACS

AN 1997:623041 CAPLUS

DN 127:244231

TI Method for treating substance abuse

IN Beasley, Charles M., Jr.; Rasmussen, Kurt; Tollefson, Gary D.

PA Eli Lilly and Company, USA; Beasley, Charles M., Jr.; Rasmussen, Kurt; Tollefson, Gary D.

SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2

DT **Patent**

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9733586	A1	19970918	WO 1997-US3404	19970310

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

CA	2248738	AA	19970918	CA 1997-2248738	19970310
AU	9720672	A1	19971001	AU 1997-20672	19970310
CN	1213308	A	19990407	CN 1997-193069	19970310
BR	9708037	A	19990727	BR 1997-8037	19970310
NO	9804196	A	19981103	NO 1998-4196	19980911

PRAI US 1996-13160 19960311
US 1996-13161 19960311
GB 1996-6615 19960329
GB 1996-6617 19960329
WO 1997-US3404 19970310

AB The invention provides a method for treating substance abuse comprising administering an effective amt. of olanzapine or pharmaceutically acceptable salt thereof to a patient in need thereof.

IT **132539-06-1**, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(olanzapine for treating substance abuse)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L21 ANSWER 44 OF 73 CAPLUS COPYRIGHT 2000 ACS

AN 1997:623040 CAPLUS

DN 127:268044

TI Olanzapine for treating autism and mental retardation

IN Beasley, Charles M., Jr.; Tollefson, Gary D.

PA Eli Lilly and Company, USA; Beasley, Charles M. Jr.; Tollefson, Gary D.

SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2

DT **Patent**

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9733585	A1	19970918	WO 1996-US19576	19961204

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN,

AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

CA 2248741	AA	19970918	CA 1996-2248741	19961204
AU 9711501	A1	19971001	AU 1997-11501	19961204
AU 709181	B2	19990826		
CN 1213970	A	19990414	CN 1996-180207	19961204
BR 9612552	A	19990720	BR 1996-12552	19961204
EP 946179	A1	19991006	EP 1996-942934	19961204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
NO 9804197	A	19981103	NO 1998-4197	19980911

PRAI US 1996-13162 19960311
WO 1996-US19576 19961204

AB The invention provides a method for treating autistic disorder and/or mental retardation comprising administering an effective amt. of olanzapine (I) to a patient in need thereof. I is preferably in Form II polymorph and orally administered. I was suspended in anhyd. EtOAc, heated to 76.degree., cooled to 25.degree., and isolated using vacuum filtration. The product was identified as Form II using x-ray powder anal. I was formulated into tablets.

IT **132539-06-1P**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(olanzapine for treating autism and metal retardation)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 45 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1997:623039 CAPLUS
DN 127:268043
TI Olanzapine for treating excessive aggression
IN Beasley, Charles M., Jr.; Tran, Pierre V.
PA Eli Lilly and Company, USA; Beasley, Charles M., Jr.; Tran, Pierre V.
SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DT **Patent**
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9733584	A1	19970918	WO 1996-US19573	19961204
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2248753	AA	19970918	CA 1996-2248753	19961204
	AU 9712846	A1	19971001	AU 1997-12846	19961204
	EP 900085	A1	19990310	EP 1996-943659	19961204
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
	CN 1213969	A	19990414	CN 1996-180206	19961204
	BR 9612549	A	19990720	BR 1996-12549	19961204
	NO 9804198	A	19981102	NO 1998-4198	19980911
PRAI	US 1996-13127	19960311			
	WO 1996-US19573	19961204			

AB The invention provides a method for treating extreme aggression comprising administering an effective amt. of olanzapine to a patient in need thereof.

IT **132539-06-1**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use);
BIOL (Biological study); PROC (Process); USES (Uses)
(crystal polymorph II; olanzapine for treating excessive aggression)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 46 OF 73 CAPLUS COPYRIGHT 2000 ACS

AN 1997:623032 CAPLUS

DN 127:283397

TI Pharmaceutical compositions for treating bipolar disorder containing olanzapine

IN Beasley, Charles M., Jr.; Tollefson, Gary D.
PA Eli Lilly and Company, USA; Beasley, Charles M., Jr.; Tollefson, Gary D.
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9733577	A1	19970918	WO 1996-US19575	19961204
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9713307	A1	19971001	AU 1997-13307	19961204
	EP 889725	A1	19990113	EP 1996-944772	19961204
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
	CN 1213966	A	19990414	CN 1996-180183	19961204
	BR 9612548	A	19990720	BR 1996-12548	19961204
	NO 9804189	A	19980911	NO 1998-4189	19980911

PRAI US 1996-13159 19960311
WO 1996-US19575 19961204

AB A method for treating bipolar disorder comprising administering an effective amt. of olanzapine (I) to a patient in need thereof. Addnl., the present invention provides a method for treating bipolar disorder, major depressive episode. I was prepd. by the reaction of 2-methyl-4-amino-10H-thieno[2,3-b][1,5]benzodiazepine hydrochloride with N-methylpiperazine in DMSO. Prepn. of coated pharmaceutical tablets contg. I were disclosed.

IT **132539-06-1P**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pharmaceutical compns. for treating bipolar disorder contg. olanzapine)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 47 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1997:594839 CAPLUS
DN 127:257606
TI Assessment of the responsiveness of individuals to modulators of the 5-HT2
receptors, especially the 5-HT2A receptor, by detection of receptor allele
DNA
IN Kerwin, Robert; Collier, David; Roberts, Gareth Wyn
PA Smithkline Beecham PLC, UK; Kerwin, Robert; Collier, David; Roberts, Gareth Wyn
SO PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9732037	A1	19970904	WO 1997-EP993	19970226
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9718789	A1	19970916	AU 1997-18789	19970226
JP 2000506009	T2	20000523	JP 1997-530621	19970226

PRAI GB 1996-4465 19960301
WO 1997-EP993 19970226

AB A method is disclosed for use in assessing, in a subject suffering from a condition which may be treated with a 5-HT2 modulator, the likelihood whether the subject will be responsive or nonresponsive to treatment with a 5-HT2 modulator. The method comprises detecting the presence or absence of DNA encoding the Tyr452 and/or His452 alleles of the 5-HT2A gene in a biol. sample obtained from the subject. Genotyping for His452Tyr polymorphism was carried out using blood samples from individuals diagnosed as suffering from schizophrenia and being treated with clozapine. The individuals were also sep. assessed for responsiveness to clozapine treatment.

IT **132539-06-1**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(5-HT2 receptor modulator responsiveness assessment by detection of receptor allele DNA)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 48 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1997:511843 CAPLUS
DN 127:117369
TI Method of predicting a subjects response to neuroleptic agents
IN Royston, Maureen Claire
PA Smithkline Beecham Plc, UK; Royston, Maureen Claire
SO PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9721833	A1	19970619	WO 1996-EP5734	19961211
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9713762	A1	19970703	AU 1997-13762	19961211
PRAI	GB 1995-25481		19951213		
	WO 1996-EP5734		19961211		

AB A method of assessing in a subject the likelihood whether said subject will be non-responsive or responsive to treatment with a drug the primary mode of action of which is via a process of altered synaptic activity, the method comprising detecting the presence or absence of DNA comprising the E2 allele of the ApoE gene, or of protein expressed by said DNA, in a biol. sample obtained from said subject. The method is exemplified with

an atypical neuroleptic agent, i.e. clozapine.

IT **132539-06-1**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug therapy of schizophrenia and detection of E2 allele of the ApoE gene for prediction of therapeutic outcome)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 49 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1997:503273 CAPLUS
DN 127:126642
TI Method for treating depression
IN Tollefson, Gary D.
PA Eli Lilly and Company, USA; Tollefson, Gary D.
SO PCT Int. Appl., 11 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9723220	A1	19970703	WO 1996-US19574	19961204
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2241153	AA	19970703	CA 1996-2241153	19961204
	AU 9712847	A1	19970717	AU 1997-12847	19961204
	AU 705834	B2	19990603		
	EP 868185	A1	19981007	EP 1996-943660	19961204
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
	CN 1205637	A	19990120	CN 1996-199221	19961204
	US 5958921	A	19990928	US 1998-91539	19980618
	NO 9802911	A	19980622	NO 1998-2911	19980622
PRAI	US 1995-9173		19951222		

WO 1996-US19574 19961204

AB The invention provides a method for treating depressive signs and symptoms comprising administering an effective amt. of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine to a patient in need thereof.

IT **132539-06-1**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. and antidepressant activity of methyl(methylpiperazinyl)thienob enzodiazepine and tablet formulation)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L21 ANSWER 50 OF 73 CAPLUS COPYRIGHT 2000 ACS

AN 1997:503266 CAPLUS

DN 127:117375

TI 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine for treating fungal dermatitis

IN Tran, Pierre V.

PA Eli Lilly and Company, USA; Tran, Pierre V.

SO PCT Int. Appl., 13 pp.
CODEN: PIXXD2

DT **Patent**

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9723221	A1	19970703	WO 1996-US20048	19961216
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2240836	AA	19970703	CA 1996-2240836	19961216
AU 9713353	A1	19970717	AU 1997-13353	19961216
JP 2000502346	T2	20000229	JP 1997-523755	19961216
EP 783890	A1	19970716	EP 1996-309201	19961217

R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
PRAI US 1995-8987 19951221
WO 1996-US20048 19961216
AB A method for treating fungal dermatitis comprises administering an effective amt. of 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (I) to a patient in need thereof. The effectiveness of I was shown in a clin. trial. Prepn. of I is described. A tablet formulation is included.
IT **132539-06-1P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(thienobenzodiazepine deriv. for fungal dermatitis treatment)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 51 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1997:443204 CAPLUS
DN 127:70845
TI Antiemetic pharmaceutical compositions containing olanzapine
IN Van Tran, Pierre
PA Lilly, Eli, and Co., USA
SO Brit. UK Pat. Appl., 19 pp.
CODEN: BAXXDU
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB 2305860	A1	19970423	GB 1996-6618	19960329

AB Antiemetic pharmaceutical compns. contg. olanzapine (I) are useful in the treatment of emesis, particularly related to chemotherapy. Thus, 270 g sample of tech. grade I (prepn. given) was suspended in 2.7 L anhyd. Et acetate and heated at 76.degree. for 30 min. The mixt was allowed to cool to 25.degree. and the resulting product was isolated and identified as form II using X-ray powder anal. Formulation of I tablets are disclosed.
IT **132539-06-1P**, Olanzapine

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiemetic pharmaceutical compns. contg. olanzapine)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 52 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1997:403057 CAPLUS
DN 127:13469
TI Olanzapine for treatment of obsessive-compulsive disorder
IN Beasley, Charles Merritt, Jr.; Tollefson, Gary Dennis
PA Lilly, Eli, and Co., USA
SO Brit. UK Pat. Appl., 18 pp.
CODEN: BAXXDU
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2305859	A1	19970423	GB 1996-6614	19960329

AB Olanzapine is useful in the treatment of obsessive-compulsive disorder. The olanzapine may be the form II olanzapine polymorph. Prepn. of the polymorph is described. Prepn. of a tablet formulation is also included.
IT **132539-06-1**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);
THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(olanzapine for treatment of obsessive-compulsive disorder)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



IT **132539-06-1D**, Olanzapine, form II polymorph
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(olanzapine polymorph for treatment of obsessive-compulsive disorder)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 53 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1997:400460 CAPLUS
DN 127:70833
TI Solvate of olanzapine
IN Larsen, Samuel D.
PA Eli Lilly and Company, USA; Lilly Industries Ltd.
SO U.S., 8 pp.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5637584	A	19970610	US 1995-410263	19950324

AB A methylene chloride solvate of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (I) which is useful for the desired anhyd. form is provided. Thus, 5.0 g of tech. grade I was suspended in

methylene chloride and heated to about 30.degree. for 30 min, then chilled
to 5.degree. and the product thus obtained was isolated by vacuum filtration.

IT **132539-06-1**, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solvate of olanzapine)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 54 OF 73 CAPLUS COPYRIGHT 2000 ACS

AN 1997:381011 CAPLUS

DN 126:347316

TI Pharmaceutical compositions of levo-enantiomers of medetomidine derivatives and their use

IN Aakerman, Karl E. O.; Jansson, Christian; Kukkonen, Jyrki; Savola, Juha-Matti; Wurster, Siegfried; Cockcroft, Victor

PA Orion-Yhtymae Oy, Finland; Aakerman, Karl E. O.; Jansson, Christian; Kukkonen, Jyrki; Savola, Juha-Matti; Wurster, Siegfried; Cockcroft, Victor

SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2

DT **Patent**

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9715302	A1	19970501	WO 1996-FI560	19961023
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI				
	CA 2232336	AA	19970501	CA 1996-2232336	19961023
	AU 9673019	A1	19970515	AU 1996-73019	19961023
	AU 707728	B2	19990715		
	EP 858338	A1	19980819	EP 1996-934847	19961023
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI

	CN 1200035	A	19981125	CN 1996-197793	19961023
	JP 2000503298	T2	20000321	JP 1997-516319	19961023
	NO 9801799	A	19980422	NO 1998-1799	19980422
	US 5994384	A	19991130	US 1998-43107	19980916
PRAI	GB 1995-21680	19951023			
	WO 1996-FI560	19961023			

OS MARPAT 126:347316

AB The levo-isomers of certain imidazole derivs. (Markush structure given), particularly medetomidine, have been found to be inverse agonists of adrenergic .alpha.-2 receptors and are therefore useful in the prevention or treatment of conditions assocd. with overexpression or hypersensitization of adrenergic .alpha.-2 receptors such as obesity, a withdrawal symptom to an adrenergic .alpha.-2 receptor agonist, a neurol. disorder, multiple system atrophy, diabetes mellitus, benign prostatic hyperplasia and drug-induced sensitization of adrenergic .alpha.-2 receptors. The pharmaceutical compn. is preferably transdermal. Levo-medetomidine (I) had opposite effect compared to adrenergic .alpha.-2 receptor agonists in the concept of coupling to the signal mols. CA2+ and cAMP and was able to reduce the activity of adrenergic .alpha.-2 receptors in human erythroleukemia. Various formulations of transdermal I.HCl is disclosed.

IT **132539-06-1**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. of levo-enantiomers of medetomidine derivs. and their use)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L21 ANSWER 55 OF 73 CAPLUS COPYRIGHT 2000 ACS

AN 1997:332391 CAPLUS

DN 126:308810

TI Pharmaceutical compositions for treating a tic disorder

IN Beasley, Charles M., Jr

PA Lilly, Eli, and Co., USA; Beasley, Charles M., Jr.

SO PCT Int. Appl., 25 pp.

CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9711700	A1	19970403	WO 1996-US14090	19960827
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM				
CA 2232559	AA	19970403	CA 1996-2232559	19960827
AU 9670131	A1	19970417	AU 1996-70131	19960827
EP 852496	A1	19980715	EP 1996-931453	19960827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 11512705	T2	19991102	JP 1996-513436	19960827

PRAI US 1995-5176 19950929
WO 1996-US14090 19960827

AB A pharmaceutical compn. for treating a tic disorder comprise administering an effective amt. of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (prepn. given) (I). A tablet contained I 10.0, magnesium stearate 0.9, microcryst. cellulose 75.0, povidone 25.0, and starch 204.1 mg.

IT **132539-06-1P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pharmaceutical compns. for treating tic disorder)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 56 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1997:324780 CAPLUS
DN 127:5106
TI Preparation of 2-methylthienobenzodiazepine as central nervous system

agent.
IN Chakrabarti, Jiban K.; Hotten, Terrence M.; Tupper, David E.
PA Lilly Industries Ltd., UK
SO U.S., 11 pp. Cont.-in-part of U.S. Ser. No. 44,844, abandoned.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5627178	A	19970506	US 1995-387997	19950213
	US 5229382	A	19930720	US 1992-890348	19920522
	US 5817655	A	19981006	US 1996-748292	19961113
	US 6008216	A	19991228	US 1998-122294	19980724
PRAI	US 1991-690143	19910423			
	US 1992-890348	19920522			
	US 1993-44844	19930408			
	GB 1990-9229	19900425			
	US 1995-387997	19950213			
	US 1996-748292	19961113			

GI



I

AB 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine (I), or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system. Compd. I is used in the treatment of schizophrenia, catatonic, delusional disorder, brief reactive psychosis, manic depression, anxiety disorder, post-traumatic stress disorder, obsessive compulsive disorder, delusions, hallucinations, and disorganized behavior. Thus, 4.3g of 4-amino-2-methyl-10H-thieno[2,3-b]benzodiazepine hydrochloride (prepn. given) was reluxed in a mixt. of 15 mL of N-methylpiperazine, DMSO, and toluene for 20 h to give 1.65g I. Formulations contg. I were described.
IT **132539-06-1P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-methyl-thieno-benzodiazepine as central nervous system agent)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 57 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1997:296931 CAPLUS
DN 126:282829
TI Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems
IN Chen, Tung-Fen; Chiang, Chia-Ming; Jona, Janan; Joshi, Priti; Ramdas, Asha
PA Cygnus, Inc., USA; Chen, Tung-Fen; Chiang, Chia-Ming; Jona, Janan; Joshi, Priti; Ramdas, Asha
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9709970	A1	19970320	WO 1996-US14739	19960913
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG				
AU 9671097	A1	19970401	AU 1996-71097	19960913
EP 907359	A1	19990414	EP 1996-932225	19960913
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE, PT, IE, FI				

PRAI US 1995-528105 19950914
US 1995-581128 19951229
WO 1996-US14739 19960913

AB High capacity drug reservoirs are provided for incorporation into transdermal drug delivery systems. The drug reservoirs are hydrogels formulated from polyurethanes crosslinked with diisocyanate crosslinking agents or cured with radiation in the presence of a photoinitiator. Drug loading as high as 65 to 70 wt.% or higher can be achieved by absorbing drug formulation into the reservoir after hydrogel synthesis. Methods for making and using transdermal systems contg. such reservoirs are provided as well. E.g., a hydrogel compn. contains olanzapine, Hypol PreMA G-50, Me laurate lauryl lactate and 1,2-butanediol.

IT **132539-06-1**, Olanzapine

RL: PEP (Physical, engineering or chemical process); POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(polyurethane hydrogel drug reservoirs for transdermal drug delivery systems)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L21 ANSWER 58 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1997:293899 CAPLUS
DN 126:268535
TI Transdermal administration of olanzapine
IN Jona, Janan; Joshi, Priti; Ramdas, Asha
PA Cygnus, Inc., USA
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9709985	A1	19970320	WO 1996-US14713	19960911
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI				
AU 9670705	A1	19970401	AU 1996-70705	19960911

PRAI US 1995-528106 19950914
WO 1996-US14713 19960911

AB Transdermal administration of olanzapine and pharmaceutically acceptable acid addn. salts thereof is described. The method involves treating an individual suffering from or susceptible to psychosis, acute mania or mild anxiety states, particularly those afflicted with schizophrenia, by administering olanzapine or a salt thereof through the skin or mucosal tissue, for a time period and at an administration rate effective to alleviate the symptoms of the disease. The drug is administered along

with a skin permeation enhancer selected from C2-6-alkanediols, fatty esters, fatty acids, and fatty alcs. Olanzapine was dissolved in a vehicle contg. 1,2-butanediol 90 and propylene glycol monolaurate 10 % and
applied to human cadaver skin using a Franz diffusion cell to demonstrate effective skin flux.

IT **132539-06-1**, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transdermal administration of olanzapine)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 59 OF 73 CAPLUS COPYRIGHT 2000 ACS

AN 1997:293898 CAPLUS

DN 126:268534

TI High capacity, superabsorbent drug reservoirs for use in transdermal drug delivery systems

IN Chen, Tung-Fen; Chiang, Chia-Ming; Jona, Janan; Joshi, Priti; Ramdas, Asha

PA Cygnus, Inc., USA; Chen, Tung-Fen; Chiang, Chia-Ming; Jona, Janan; Joshi, Priti; Ramdas, Asha

SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2

DT **Patent**

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9709971	A2	19970320	WO 1996-US14784	19960913
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG				
	AU 9672388	A1	19970401	AU 1996-72388	19960913
PRAI	US 1995-528655		19950914		
	US 1995-582843		19951229		
	WO 1996-US14784		19960913		

AB High capacity drug reservoirs are provided for incorporation into transdermal drug delivery systems. The drug reservoirs are comprised of a superabsorbent material, typically a crosslinked polymer, which is capable of absorbing an amt. of drug formulation corresponding to at least 15 g formulation per g of material. Methods for making and using transdermal systems contg. such reservoirs are provided as well. Olanzapine was dissolved in a vehicle contg. lauric acid 10, Me laurate 45, and 1,2-butanediol 45 % and absorbed onto a highly absorbent maleic anhydride-isobutylene copolymer film. The samples were cut and applied to human cadaver skin using a Franz diffusion cell to demonstrate effective skin fluxes.

IT **132539-06-1**, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(superabsorbent drug reservoirs for use in transdermal drug delivery systems)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 60 OF 73 CAPLUS COPYRIGHT 2000 ACS

AN 1997:169159 CAPLUS

DN 126:195254

TI Use of .alpha.2-adrenergic drugs to prevent adverse effects of NMDA antagonist- or schizophrenia-associated NMDA receptor hypofunction (NRH)

IN Olney, John W.; Farber, Nuri B.

PA Washington University, USA

SO U.S., 19 pp.
CODEN: USXXAM

DT **Patent**

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5605911	A	19970225	US 1995-381334	19950131

AB Methods and compns. are disclosed for treating or preventing adverse CNS effects produced by NMDA receptor hypofunction (NRH), including hypofunction induced by NMDA antagonist drugs, and hypofunction occurring as a causative or aggravating factor in schizophrenia. One method of this

invention comprises administering an .alpha.2-adrenergic receptor agonist drug along with an NMDA antagonist drug. The NMDA antagonist drug exerts a primary benefit in reducing excitotoxic brain damage, alleviating neuropathic pain, or preventing or avoiding tolerance or addiction to various types of drugs. The .alpha.2 agonist drug acts as a secondary or "safener" drug, to prevent the neurotoxic side effects that would be caused by the NMDA antagonist in the absence of the safener drug. Another method disclosed herein involves the use of an .alpha.2 agonist drug, by itself, to combat a different and naturally-occurring form of NMDA receptor hypofunction which occurs as a causative or aggravating mechanism in people suffering from schizophrenia. Although .alpha.2 agonists are usually not effective in treating long-standing cases of chronic schizophrenia, where pathol. changes in the brain have already reached or approached maximal levels, .alpha.2 agonists can be administered early in the illness, such as at the first signs of schizophrenic illness, and continuously or intermittently thereafter to prevent the development or worsening of pathol. brain changes.

IT **132539-06-1**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antipsychotic drug effect in protection against NMDA receptor hypofunction)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L21 ANSWER 61 OF 73 CAPLUS COPYRIGHT 2000 ACS

AN 1997:169158 CAPLUS

DN 126:242879

TI Olanzapine for the treatment of psychological conditions

IN Beasley, Charles M., Jr.; Chakrabarti, Jiban K.; Hotten, Terrence M.; Tupper, David E.

PA Eli Lilly and Company, USA; Lilly Industries Ltd.

SO U.S., 10 pp. Cont.-in-part of U.S. Ser. No. 44,844, abandoned.
CODEN: USXXAM

DT **Patent**

LA English

FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	US 5605897	A	19970225	US 1995-387498	19950213
	US 5229382	A	19930720	US 1992-890348	19920522
	US 5817656	A	19981006	US 1996-748293	19961113
	US 5817657	A	19981006	US 1996-748294	19961113
PRAI	US 1991-690143	19910423			
	US 1992-890348	19920522			
	US 1993-44844	19930408			
	GB 1990-9229	19900425			
	US 1995-387498	19950213			

AB Olanzapine (I) or an acid salt thereof, is of particular use in the relatively safe and effective treatment of a wide range of disorders of the central nervous system. I is an antagonist of dopamine at D-1 and D-2 receptors and in addn. has antimuscarinic anticholinergic properties and antagonist activity at 5HT-2 receptor sites and at noradrenergic .alpha.-receptors. These properties indicate that I is a potential neuroleptic with relaxant, anxiolytic, and anti-emetic properties. Formulations for tablets, capsules, and injections contg. I are provided. Clin. studies showed successful results for treatment of schizophrenic patients.

IT **132539-06-1P**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(olanzapine for treatment of CNS disorders)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L21 ANSWER 62 OF 73 CAPLUS COPYRIGHT 2000 ACS

AN 1997:90507 CAPLUS

DN 126:108941

TI Olanzapine for treating anorexia

IN Beasley, Charles M., Jr.

PA Lilly, Eli, and Co., USA; Beasley, Charles M., Jr.

SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2

DT **Patent**

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9638152	A1	19961205	WO 1996-US7467	19960523
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	CA 2222073	AA	19961205	CA 1996-2222073	19960523
	AU 9658725	A1	19961218	AU 1996-58725	19960523
	EP 831835	A1	19980401	EP 1996-920403	19960523
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
	JP 08325151	A2	19961210	JP 1996-136441	19960530
PRAI	US 1995-457249	19950601			
	WO 1996-US7467	19960523			

AB The invention provides a method for treating a clin. significant decrease in appetite comprising administering a pharmaceutically effective amt. of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (olanzapine). X-ray powder diffraction pattern of substantially pure cryst. anhyd. form of olanzapine is provided. A tablet contg. 7.5 mg olanzapine was formulated.

IT **132539-06-1**, Olanzapine
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(olanzapine for treating anorexia)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 63 OF 73 CAPLUS COPYRIGHT 2000 ACS

AN 1996:713012 CAPLUS

DN 125:317310

TI Method for determining the responsiveness of individuals to 5-HT2 receptor-modulating agents

IN Kerwin, Robert; Collier, David; Roberts, Gareth Wyn

PA Smithkline Beecham Plc, UK

SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2

DT **Patent**

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9631621	A2	19961010	WO 1996-EP1437	19960401
	WO 9631621	A3	19961205		
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	AU 9654991	A1	19961023	AU 1996-54991	19960401
	JP 11503018	T2	19990323	JP 1996-529970	19960401
PRAI	GB 1995-7230	19950407			
	WO 1996-EP1437	19960401			

AB A method is disclosed for assessing whether a subject is likely to be responsive to treatment with a therapeutic agent which acts at a 5-HT2 receptor. The methodol. involves detection of the presence or absence of DNA encoding the S68 allele and/or the C68 allele of the 5-HT2C gene.

IT **132539-06-1**, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C68/S68 allele of 5-HT2C gene detection in 5-HT2 receptor-modulating agent responsiveness detn. for humans treatable with 5-HT2 receptor-modulating agents)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 64 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1996:689366 CAPLUS
DN 125:309062
TI Olanzapine for treatment of dyskinesias
IN Beasley, Charles Merrit Jr
PA Lilly, Eli, and Co., USA
SO Eur. Pat. Appl., 25 pp.
CODEN: EPXXDW
DT **Patent**
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI EP 738514 A1 19961023 EP 1996-302711 19960418
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
US 5776928 A 19980707 US 1995-422177 19950421
WO 9638151 A1 19961205 WO 1995-US6859 19950530
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
CA 2219902 AA 19961205 CA 1995-2219902 19950530
AU 9526936 A1 19961218 AU 1995-26936 19950530
AU 707858 B2 19990722
EP 828494 A1 19980318 EP 1995-922148 19950530
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV
CN 1185108 A 19980617 CN 1995-197876 19950530
HU 77907 A2 19981028 HU 1998-1173 19950530
JP 11506096 T2 19990602 JP 1995-536420 19950530
WO 9632948 A1 19961024 WO 1996-US5390 19960418
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN
RW: KE, LS, MW, SD, SZ, UG, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
CA 2218062 AA 19961024 CA 1996-2218062 19960418
AU 9655555 A1 19961107 AU 1996-55555 19960418
JP 11504014 T2 19990406 JP 1996-531914 19960418
NO 9704766 A 19971209 NO 1997-4766 19971015
FI 9703987 A 19971017 FI 1997-3987 19971017
PRAI US 1995-422177 19950421
WO 1995-US6859 19950530
WO 1996-US5390 19960418

AB Use of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (olanzapine) or a pharmaceutically acceptable salt thereof, for the manuf. of a medicament for treating a dyskinesia, is disclosed. Oral and injection formulations are provided.

IT **132539-06-1P**, Olanzapine
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(olanzapine for treatment of dyskinesias)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 65 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1996:679179 CAPLUS
DN 125:309063
TI Olanzapine for treatment of nicotine withdrawal syndromes
IN Rasmussen, Kurt
PA Lilly, Eli, and Co., USA
SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 738515	A1	19961023	EP 1996-302712	19960418
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5696115	A	19971209	US 1995-422202	19950421
	WO 9632947	A1	19961024	WO 1996-US5379	19960418
	W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2218019	AA	19961024	CA 1996-2218019	19960418
	AU 9655547	A1	19961107	AU 1996-55547	19960418
	JP 11504012	T2	19990406	JP 1996-531909	19960418
PRAI	US 1995-422202	19950421			
	WO 1996-US5379	19960418			

AB Use of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (olanzapine) or a pharmaceutically acceptable salt thereof, for the manuf. of a medicament for treating a condition resulting from the cessation and withdrawal from the use of nicotine, is disclosed. Formulations contg. olanzapine for oral and i.m. administration, are provided.

IT **132539-06-1P**, Olanzapine
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(olanzapine for treatment of nicotine withdrawal syndromes)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-

(9CI) (CA INDEX NAME)



L21 ANSWER 66 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1996:660927 CAPLUS
DN 125:284961
TI Granule formulation for olanzapine
IN Lange, Hans Joerg
PA Lilly, Eli, and Co., USA
SO Eur. Pat. Appl., 11 pp.
CODEN: EPXXDW
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 733368	A1	19960925	EP 1996-301998	19960322

R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
PRAI US 1995-410265 19950324
US 1995-426343 19950421

AB The invention provides a pharmaceutically elegant granule formulation of olanzapine and a process for providing a pharmaceutically acceptable liq. formulation of olanzapine. The solid granule formulation comprises olanzapine as an active ingredient, mannitol, hydroxypropyl Me cellulose, and a pharmaceutically acceptable surfactant, provided that the size of the granules is such that not more than 5% are greater than 500 .mu.m and not more than 10% are less than 75 .mu.m. Granules were prepd. and packaged in a sachet to have ingredients of olanzapine 2.5, D-mannitol 234.97, hydroxypropyl Me cellulose 12.5, and Polysorbate 20 0.028 mg. The granules can be dissolved in an acidic mineral water or juice.

IT **132539-06-1P**, Olanzapine
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(granule formulation for olanzapine)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 67 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1996:660926 CAPLUS
DN 125:284960
TI Oral olanzapine formulation
IN Cochran, George Randall; Morris, Tommy Clifford
PA Lilly, Eli, and Co., USA
SO Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DT **Patent**
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 733367	A1	19960925	EP 1996-301997	19960322
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	WO 9629995	A1	19961003	WO 1996-US3918	19960322
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2216372	AA	19961003	CA 1996-2216372	19960322
	AU 9654280	A1	19961016	AU 1996-54280	19960322
	AU 696601	B2	19980917		
	GB 2313783	A1	19971210	GB 1997-19817	19960322
	GB 2313783	B2	19981118		
	DE 19681287	T	19980319	DE 1996-19681287	19960322
	CN 1179102	A	19980415	CN 1996-192778	19960322
	BR 9607791	A	19980707	BR 1996-7791	19960322
	AT 9609022	A	19990215	AT 1996-9022	19960322
	AT 405606	B	19991025		
	JP 11502848	T2	19990309	JP 1996-529533	19960322
	SE 9703206	A	19970905	SE 1997-3206	19970905
	LT 4350	B	19980525	LT 1997-149	19970916
	FI 9703749	A	19970922	FI 1997-3749	19970922
	NO 9704363	A	19971117	NO 1997-4363	19970922
	DK 9701090	A	19971112	DK 1997-1090	19970923
	LV 11983	B	19980720	LV 1997-199	19971014
PRAI	US 1995-410465	19950324			
	WO 1996-US3918	19960322			

AB The invention provides a pharmaceutically elegant solid oral formulation

of olanzapine and a process for making such formulation. The formulation comprises olanzapine as an active ingredient intimately mixed with a bulking agent, binder, disintegrant, and a lubricant; wherein such solid oral formulation is coated with a polymer selected from the group consisting of hydroxypropyl Me cellulose, sodium CM-cellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, dimethylaminoethyl methacrylate-Me acrylate copolymer, Et acrylate-Me methacrylate copolymer, Me cellulose, and Et cellulose. A tablet contained olanzapine 1, lactose 67.43, hydroxypropyl cellulose 3.4, Crospovidone 4.25, microcryst. cellulose 8.5, Mg stearate 0.42, hydroxypropyl Me cellulose (as subcoating agent) 1.7, color mixt. (as coating agent) 3.47 mg/tablet, Carnauba wax (as polishing agent) trace, and edible Blue ink (for imprinting) trace.

IT **132539-06-1P**, Olanzapine
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(oral olanzapine formulation)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L21 ANSWER 68 OF 73 CAPLUS COPYRIGHT 2000 ACS

AN 1996:656468 CAPLUS

DN 125:301028

TI Preparation of olanzapine solvates

IN Bunnell, Charles Arthur; Hendriksen, Barry Arnold; Hotten, Terrence Michael; Larsen, Samuel Dean; Tupper, David Edward

PA Lilly, Eli, and Co., USA; Lilly Industries Ltd.

SO Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW

DT **Patent**

LA English

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 733634	A1	19960925	EP 1996-301999	19960322
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5631250	A	19970520	US 1995-410474	19950324
US 5703232	A	19971230	US 1996-586431	19960116

WO 9630374 A1 19961003 WO 1996-US3854 19960322
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI
RW: KE, LS, MW, SD, SZ, UG, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
AU 9652578 A1 19961016 AU 1996-52578 19960322
AU 9654279 A1 19961016 AU 1996-54279 19960322
AU 706471 B2 19990617
GB 2313835 A1 19971210 GB 1997-19819 19960322
GB 2313835 B2 19980916
DE 19681286 T 19980402 DE 1996-19681286 19960322
BR 9607790 A 19980707 BR 1996-7790 19960322
JP 11502535 T2 19990302 JP 1996-529532 19960322
AT 9609021 A 20000115 AT 1996-9021 19960322
SE 9703205 A 19970905 SE 1997-3205 19970905
FI 9703750 A 19970922 FI 1997-3750 19970922
NO 9704365 A 19970922 NO 1997-4365 19970922
DK 9701089 A 19971112 DK 1997-1089 19970923
PRAI US 1995-409566 19950324
US 1995-410474 19950324
WO 1996-US3854 19960322
WO 1996-US3917 19960322
AB The invention provides MeOH, EtOH, and PrOH solvates of olanzapine with improved properties characterized by x-ray spectra.
IT **132539-06-1P**, Olanzapine
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of olanzapine solvates)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 69 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1996:644040 CAPLUS
DN 125:275918
TI Preparation of crystalline olanzapine
IN Bunnell, Charles Arthur; Hendriksen, Barry Arnold; Larsen, Samuel Dean
PA Lilly, Eli, and Co., USA; Lilly Industries Ltd.
SO Eur. Pat. Appl., 10 pp.

CODEN: EPXXDW
DT **Patent**
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 733635	A1	19960925	EP 1996-302000	19960322
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CA 2214005	AA	19961003	CA 1996-2214005	19960322
WO 9630375	A1	19961003	WO 1996-US3917	19960322
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9652578	A1	19961016	AU 1996-52578	19960322
AU 9654279	A1	19961016	AU 1996-54279	19960322
AU 706471	B2	19990617		
GB 2313835	A1	19971210	GB 1997-19819	19960322
GB 2313835	B2	19980916		
DE 19681286	T	19980402	DE 1996-19681286	19960322
CN 1179160	A	19980415	CN 1996-192775	19960322
BR 9607790	A	19980707	BR 1996-7790	19960322
JP 11502535	T2	19990302	JP 1996-529532	19960322
AT 9609021	A	20000115	AT 1996-9021	19960322
SE 9703205	A	19970905	SE 1997-3205	19970905
LV 12018	B	19980920	LV 1997-163	19970908
LT 4349	B	19980525	LT 1997-148	19970916
FI 9703750	A	19970922	FI 1997-3750	19970922
NO 9704365	A	19970922	NO 1997-4365	19970922
DK 9701089	A	19971112	DK 1997-1089	19970923

PRAI US 1995-409566 19950324
US 1995-410474 19950324 5736541
WO 1996-US3854 19960322 5631250
WO 1996-US3917 19960322

AB The invention provides a pharmaceutically elegant stable polymorph of olanzapine by pptn. from EtOAc.

IT **132539-06-1P**, Olanzapine
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of cryst. olanzapine)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 70 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1995:913754 CAPLUS
DN 123:350255
TI Thieno[1,5]benzoidiazepine use
IN Greenwood, Beverley; Nelson, David L. G.
PA Lilly, Eli, and Co., USA
SO U.S., 5 pp.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5457101	A	19951010	US 1994-253658	19940603
	ZA 9504358	A	19961129	ZA 1995-4358	19950529
	IL 113912	A1	19990411	IL 1995-113912	19950529
	NO 9502130	A	19951204	NO 1995-2130	19950530
	CA 2150517	AA	19951204	CA 1995-2150517	19950530
	AU 9520424	A1	19951214	AU 1995-20424	19950531
	AU 684924	B2	19980108		
	HU 71598	A2	19960129	HU 1995-1600	19950601
	CN 1119101	A	19960327	CN 1995-106142	19950601
	EP 685233	A2	19951206	EP 1995-303788	19950602
	EP 685233	A3	19960403		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 07330608	A2	19951219	JP 1995-136571	19950602

PRAI US 1994-253658 19940603

AB The compd. 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine (I), or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of certain gastrointestinal disorders. Hard gelatin capsules were formulated contg. I 5.0, silicone 2.9, and starch flowable 292.1 mg.

IT **132539-06-1**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine for treatment of gastrointestinal disorders)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 71 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1994:465597 CAPLUS
DN 121:65597
TI Sustained-release microsphere containing antipsychotic and process for producing the same
IN Kino, Shigemi; Osajima, Tomonori; Mizuta, Hiroaki
PA Yoshitomi Pharmaceutical Industries, Ltd., Japan
SO PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DT **Patent**
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9410982	A1	19940526	WO 1993-JP1673	19931115
W: CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2148823	AA	19940526	CA 1993-2148823	19931115
CA 2148823	C	19990309		
EP 669128	A1	19950830	EP 1993-924827	19931115
EP 669128	B1	20000105		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 188375	E	20000115	AT 1993-924827	19931115
US 5656299	A	19970812	US 1995-443021	19950517
US 5871778	A	19990216	US 1997-812544	19970307
PRAI JP 1992-332441	19921117			
WO 1993-JP1673	19931115			
US 1995-443021	19950517			

AB A sustained-release microsphere produced by enclosing a hydrophobic antipsychotic such as bromperidol or haloperidol in a base comprising a biocompatible polymer such as polylactic acid or a lactic acid/glycolic acid copolymer. It can exhibit a desired pharmacol. effect, where a long-term administration is necessary, by injecting once every 1 to 8 wk instead of every day. As a result, a remarkable improvement can be expected in the compliance during maintenance therapy. In addn., the use of the biocompatible polymer serves to entirely dispense with surgical operations such as implantation, facilitates hypodermic and i.m. injection just like the case of suspending injection, and can dispense with the withdrawal of the microsphere. Furthermore, the microsphere can be administered with little aversion and pain.

IT **132539-06-1P**, Olanzapine

(Sustained-release microspheres, manuf. of, biocompatible polymers in)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine,
2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 72 OF 73 CAPLUS COPYRIGHT 2000 ACS
AN 1994:435640 CAPLUS
DN 121:35640
TI Pharmaceutical compounds
IN Fairhurst, John; Hotten, Terrence M.; Tupper, David E.
PA Lilly Industries Ltd., UK
SO Can. Pat. Appl., 15 pp.
CODEN: CPXXEB
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2097016	AA	19931130	CA 1993-2097016	19930526
	NO 9301917	A	19931130	NO 1993-1917	19930526
	AU 9339807	A1	19931202	AU 1993-39807	19930526
	AU 668159	B2	19960426		
	EP 582368	A1	19940209	EP 1993-304102	19930526
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 06087862	A2	19940329	JP 1993-126429	19930528
	CN 1085903	A	19940427	CN 1993-108212	19930528
	CN 1043994	B	19990707		
	HU 66180	A2	19940928	HU 1993-1579	19930528
	IL 105827	A1	19970218	IL 1993-105827	19930528
	CZ 282783	B6	19971015	CZ 1993-1024	19930528
	US 6034078	A	20000307	US 1997-886847	19970701
PRAI	GB 1992-11379	19920529			
	GB 1993-9025	19930430			
	US 1993-68007	19930527			
	US 1994-335431	19941107			

OS MARPAT 121:35640
GI



I

AB Thienobenzodiazepine pharmaceutical compds. of the formula thienobenzodiazepine I wherein R1 is hydrogen or halo, and R2 is C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-6 cycloalkyl optionally substituted by 1 to 3 C1-4 alkyl groups, C3-6 cycloalkyl-C1-4 alkyl in which the cycloalkyl group is optionally substituted by 1 to 3 C1-4 alkyl groups, or optionally substituted phenyl-C1-4 alkyl; or a salt thereof are prepd. as wide range treatment of central nervous system disorders.

IT **132539-06-1**
RL: RCT (Reactant)
(alkylation of, in the prepn. of drug of wide range treatment of central nervous system disorders)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)



L21 ANSWER 73 OF 73 CAPLUS COPYRIGHT 2000 ACS

AN 1992:83703 CAPLUS

DN 116:83703

TI Preparation of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine

IN Chakrabarti, Jiban Kumar; Hotten, Terrence Michael; Tupper, David Edward

PA Lilly Industries Ltd., UK

SO Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW

DT **Patent**

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 454436	A1	19911030	EP 1991-303679	19910424
	EP 454436	B1	19950913		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AU 9175186	A1	19911107	AU 1991-75186	19910422
	AU 643267	B2	19931111		
	IL 97912	A1	19951031	IL 1991-97912	19910422
	IL 112575	A1	19990817	IL 1991-112575	19910422
	FI 9101986	A	19911026	FI 1991-1986	19910424
	CA 2041113	AA	19911026	CA 1991-2041113	19910424
	CA 2041113	C	19980714		
	NO 9101624	A	19911028	NO 1991-1624	19910424
	NO 178766	B	19960219		
	NO 178766	C	19960529		
	CN 1056693	A	19911204	CN 1991-103346	19910424
	CN 1028429	B	19950517		
	HU 60503	A2	19920928	HU 1991-1372	19910424
	HU 212416	B	19960628		
	ZA 9103085	A	19921230	ZA 1991-3085	19910424
	JP 07089965	A2	19950404	JP 1991-228215	19910424
	JP 2527860	B2	19960828		
	CZ 279937	B6	19950913	CZ 1991-1168	19910424
	ES 2078440	T3	19951216	ES 1991-303679	19910424
	SK 279196	B6	19980708	SK 1991-1168	19910424
	RU 2043992	C1	19950920	RU 1992-5052762	19920925
	LV 10262	B	19950420	LV 1993-517	19930608
	FI 9701316	A	19970327	FI 1997-1316	19970327
PRAI	GB 1990-9229	19900425			
	IL 1991-97912	19910422			
	FI 1991-1986	19910424			

OS MARPAT 116:83703

AB Title compd. (I) useful for treatment of a disorder of the central nervous system (no data) was prepd. 4-Amino-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine-HCl (prepn. given) was refluxed in N-methylpiperazine, DMSO and MePh, under N atm. for 20 h to give I. Pharmaceutical formulations contg. I are given.

IT **132539-06-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as nervous system agent)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2000 ACS
RN 132539-06-1 REGISTRY
CN 10H-Thieno[2,3-b][1,5]benzodiazepine,
2-methyl-4-(4-methyl-1-piperazinyl)-
(9CI) (CA INDEX NAME)
OTHER NAMES:
CN LY 170053
CN **Olanzapine**
CN Zyprexa
FS 3D CONCORD
MF C17 H20 N4 S
CI COM
SR US Adopted Names Council
LC STN Files: ADISINSIGHT, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA,
CANCERLIT, CAPLUS, CBNB, CIN, DDFU, DRUGNL, DRUGPAT, DRUGU,
DRUGUPDATES,
EMBASE, IMSDIRECTORY, IPA, MEDLINE, MRCK*, PHAR, PROMT, RTECS*,
TOXLINE,
TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)



296 REFERENCES IN FILE CA (1967 TO DATE)
8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
300 REFERENCES IN FILE CAPLUS (1967 TO DATE)